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Gender and Cocaine Use Influence the Expression of Urinary Markers of Inflammation
and Oxidative Stress
Marie Meagher Bourgeois
Abstract

The purpose of this study was to investigate whether or not gender differences
may be present in the expression of a number of urinary proteins which may serve as
markers of inflammation and oxidative stress. Males and females have different patterns
of illness and different life spans, suggesting basic biological traits exert significant
control on the incidence of rhabdomyolysis, renal failure, atherosclerosis, myocardial
ischemia, myocardial contraction band formation, autoimmune disorders and general
inflammatory diseases. Men are at greater risk for cardiovascular disease; however
women, particularly elderly women, have higher fatality rates due to heart failure. Renal
diseases progress far more quickly in men, possibly due to testosterone. Men also have
higher kidney bulk related to androgen expression. Gender disparity may be most
obvious in autoimmune disorders; of the estimated 8.5 million people diagnosed with
autoimmune disorders, approximately 80% are women. Hashimoto’s thyroiditis, the most
common form of hypothyroidism, is up to 10 times more common in women. Systemic
Lupus Erythematosus (SLE), an autoimmune disease characterized by acute and chronic
inflammation, is 9 times more common in women. Rheumatoid arthritis (RA), an
xii

autoimmune disease affecting approximately 1.3 million people in the United States, is
four times more common in women. Diabetes mellitus (DM), affecting more than 17
million people – the majority of which are women, is linked to microvascular and
macrovascular diseases such as kidney failure, strokes and atherosclerosis. These
conditions are linked to physiological changes that may alter the expression of certain
biomarkers of inflammation and oxidative stress.
Over the past several decades, it has become increasingly clear that the role of
diet, smoking, and other lifestyle choices clearly influence the etiology and
pathophysiology of these diseases. The use of drugs, both licit and illicit, has been clearly
linked to many of these diseases. Illicit substances, particularly cocaine, have been
demonstrated to produce pathophysiological changes to many systems in the body which
can greatly influence the progression of existing and drug-induced disease states leading
to systemic damage. A relationship between the expression of markers of inflammation,
oxidative stress, cardiac damage, or other systemic injury, gender and cocaine use has not
been clearly established.
Urine is an important medium for assessment of general health status. It has
classically been used to monitor disease states; glucosuria as an indicator of diabetes and
renal dysfunction, microorganisms signifying urinary tract or bladder infection, and
biomarkers such as human chorionic gonadotropin to confirm pregnancy. Recently urine
has been used to assess biomarker expression and disease states. Urine is an ideal clinical
tool for toxicological screens; it is readily accessible, non invasive and typically supplied
in sufficient quantity to accommodate multiple tests. In this study, urine specimens were
collected and analyzed for creatinine, cocaine, total protein, aldosterone, c-reactive
xiii

protein (hsCRP), myeloperoxidase (MPO), microalbumin (MAB), neutrophil gelatinaseassociated lipocalin (NGAL), heat shock protein 90α (hsp90α), vascular endothelial
growth factor (VEGF), myoglobin, pro atrial natriuretic peptide (proANP) and
interleukins 1α, 1 β , and 6 using ELISA and colorimetric assays.
Urine specimens that tested negative for all illicit substances in the standard
National Institute on Drug Abuse (NIDA) 10 panel showed differences in a number of
these biomarkers which strongly suggested significant differences between males and
females for aldosterone, IL1α and IL1β. In addition, significance is suggested for MPO
and CRP. Although sex specific differences in serum expression have been noted for
some of the markers in both animal and human models, this has not been previously
demonstrated in human urine. This may have implications for what is typically referred to
as ‘normal’ values. Gender specific differences were not apparent in urine specimens
that tested positive for cocaine. Also, in males only, the levels of myoglobin and
aldosterone significantly increased.
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Chapter 1.0
Introduction

In 2001, the Institute of Medicine stated that gender is a „basic human variable‟
that should be considered in every facet of research design [1]. Significant gender
dimorphism has been documented in cardiovascular, renal and autoimmune diseases [28]. Higher male susceptibility to cardiovascular disease may be due to genetic, hormonal,
or lifestyle factors or through a combination of mechanisms [9, 10]. Sex-based
differences in the clinical presentation, diagnosis, and treatment outcomes of cardiac
disease have long been recognized [11]. Gender differences in lifestyle risk factors (e.g.
smoking, exercise and diet) appear to contribute to gender disparities; however, these
lifestyle factors do not completely account for the dimorphism. Despite the fact that there
is a higher incidence of cardiovascular diseases in men in general, the total number of
deaths from cardiovascular disease has been higher for women than for men [12].
Coronary artery disease is the leading cause of death in women. More than twice as many
women die from cardiovascular disease as from all forms of cancer combined. Men are
more likely than women to suffer from hypertension. Multiple physiological alterations
have been noted in hypertensive individuals; these include renal disturbances,
neurohormonal and adrenergic disruption, endothelial dysfunction, systemic
1

inflammation, and increased oxidative stress. Increased creatinine, CRP, aldosterone and
proANP are often seen in hypertension. CRP is an acute phase inflammatory marker
considered indicative of atherosclerosis and AMI. ProANP is found in atrial myocytes
and regulates blood pressure by opposing aldosterone. Proteinuria is common in renal
and cardiovascular disease. Elevated urine protein concentrations are linked to increased
IL 6 production and heart failure. MPO is another inflammatory marker; it is used to
predict the risk of AMI in the absence of cardiac necrosis. Hsp90α, a cytosolic chaperone
molecule found in cardiac tissue, is linked to oxidative stress. It is inhibited by estradiol
(E2). VEGF is inducible by ischemia and anoxia; it is often elevated along with
microalbumin. Microalbuminuria is associated with cardiovascular disease. It is induced
by vasodilation and hypoxia-inducible factors. E2 promotes vasodilation. Myoglobin is
the first marker released following myocardial necrosis and cardiac dysfunction. IL1 α
and IL1β are proinflammatory cytokines stimulated by hepatic acute phase cytokines
such as CRP that induce IL6. Another example of gender influence can be seen in the
prevalence and progression of many renal diseases [4, 13].
The majority of chronic renal diseases occur more commonly in men and progress
far more quickly. There is no discernible gender disparity in acute kidney disease rates.
Chronic Kidney Disease (CKD) is one of the few chronic renal diseases that occur more
commonly in women. CKD can lead to End Stage Renal Disease (ESRD) if it is not
treated. The physiology behind gender differences in renal disease is unclear, but
differences in kidney size and physiology, coupled with lifestyle factors and the
vasoprotective effects of estrogen, have been implicated [1, 14-19]. Estrogen is thought
to suppress the growth of renal scar tissue by inhibiting the production of collagen.
2

Interestingly, this female advantage in chronic kidney disease disappears when the
women suffer from diabetes mellitus (DM). CKD is uncommon in premenopausal
women. The rate of CKD increases as estrogen levels fall; however, this may be the
result of the relative ratio of androgen to estrogen rather than the absolute level of
estrogen. It is thought that the androgen to estrogen ratio determines the effect on the
diabetic kidney. Unlike their non-diabetic counterparts, women with DM are found to
have similar rates of kidney disease as males. DM is an increasingly common cause of
kidney failure in developed countries. Increased renin–angiotensin system (RAS) activity
is thought to play an important role in both the hemodynamic and nonhemodynamic
pathways involved in organ damage, particularly for diabetes. RAS blockade has
demonstrated nephroprotective properties in diabetic individuals. Two mechanisms for
promoting vasoconstriction are RAS activation and nitric oxide (NO) pathway disruption.
Hyperglycemia disrupts NO-mediated relaxation; despite this interaction, baseline renal
vasodilation is common in diabetes [20]. Hypertension is common in diabetics; increased
aldosterone concentration in urine is a risk factor for renal disease. Creatinine can be used
to assess glomerular filtration rate. Increased concentrations are seen in DM,
hypertension and impaired renal function. Normal urine does not have substantial protein;
proteinuria is considered suggestive of renal disease. Microalbuminuria is often seen in
renal dysfunction, as is elevated VEGF. Myoglobinuria is common in rhabdomyolysis
and renal failure. CRP and MPO, inflammatory markers, are often elevated in renal
disease. NGAL is the earliest responding marker in acute kidney injury; it is also elevated
in CKD, some forms of lupus and urinary tract infections. Hsp90α, induced by heat
shock, inflammation and oxidative stress, is often upregulated by renal disease. IL1 α and
3

IL1 β, endogenous pyrogens, may be elevated in cases of renal disease. IL 6 acts
synergistically with both IL1 subunits. The interleukins may also be elevated in
autoimmune disorders.
A common feature of autoimmune diseases in both humans and experimental
animals is that females are far more susceptible to autoimmune conditions when
compared to males. In several animal models, estrogens promote B cell mediated
autoimmune diseases. Androgens exert an inhibitory effect in the same models. Although
the reason is unclear, females tend to secrete higher levels of interleukins such as IL1 α
and IL1 β. Females display heightened immune responses not only to foreign antigens
but also to self-antigens. Estrogens induce T and B cells imbalances; they appear to
induce hypoactivity in subsets of T cell and hyperactivity in B cells. This may be the
underlying basis for estrogen induced autoimmunity. Of the 8.5 million Americans
diagnosed with autoimmune disorders, approximately 80% are women [21]. Rheumatoid
arthritis (RA) is 4 times more common in women, systemic lupus erythematosus (SLE) is
nine times more common in women and some forms of thyroiditis are 10 times more
common in women compared with men [22, 23]. Insulin dependent DM is also more
common in women than it is in men. Studies have shown that a disparity exists between
male and female diabetics, particularly in the control of modifiable risk factors such as
blood pressure, serum glucose and cholesterol levels [16, 24]. Some researchers believe
this is why death due to heart disease has decreased among diabetic men but not in
women. Creatinine is often elevated in DM. CRP and MPO may be elevated in cases of
inflammatory immune diseases such as RA and SLE. CRP may be a surrogate marker of
SLE activity and may be useful to monitor the course of the disease. NGAL often
4

increases in tandem with MPO. Hsp90α, upregulated by oxidative stress and
inflammation, may increase with autoimmune disease. VEGF is another cytokine
inducible by inflammation. Myoglobinuria may be seen in DM and other autoimmune
disease. Subclinical inflammatory reaction has been shown to precede DM; IL1 α, IL 1 β,
and IL6 are inflammatory cytokines. Studies have shown that systemic injection of IL1α
and IL1 β induces the symptoms of systemic inflammation (e.g. fever, joint pain,
headaches, neutrophilia and increases in circulating cytokines). Systemic and chronic
inflammation are thought to contribute to the development of atherosclerosis and CHD.
The plurality of these conditions has been linked to inflammation and oxidative stress and
may result in the release of biomarkers into blood and other body fluids [2-4, 13, 22, 23,
25-30].
Inflammation is one of the most prominent forms of oxidative damage. Reactive
oxygen species (ROS) produced by endothelial cells, neutrophils and macrophages can
stimulate the activation of proinflammatory transcription factors and induce the
production of inflammatory cytokines such as IL1 and IL6. Inflammation begins with
hyperemia, edema, and adherence of the circulating white blood cells to endothelial cells.
Local inflammatory response is typically accompanied by systemic changes that include
hyperemia, leukocytosis, and induction of acute-phase reactants like CRP. Chronic
inflammation is not confined to a particular tissue; it involves the endothelium and
multiple organ systems. High levels of oxidative stress and inflammation can increase the
probability of early incidence of multiple disease states, including atherosclerosis,
Parkinson's disease, heart failure, myocardial infarction, Alzheimer's disease, fragile X
syndrome and chronic fatigue syndrome (Figure 1).
5

Figure 1. Conditions Associated with Inflammation and Oxidative Stress

Oxidative stress (OS) describes the level of oxidative damage in a cell, tissue, or
organ, caused by ROS. The damage can affect everything from specific molecules to
entire organisms. ROS such as free radicals and peroxides come from the metabolism of
oxygen and are endogenous in all aerobic organisms. The rate at which damage occurs is
primarily determined by the clearance of generated ROS by antioxidants. The rate of
damage depends on the level of repair enzyme. Most are by-products of essential
metabolic reactions such as mitochondrial energy generation and hepatic cytochrome P450 detoxification reactions. Exogenous sources of ROS include lifestyle choices
6

(cigarette smoking, alcohol consumption, dietary, etc.), environmental exposures
(automotive emissions, industrial pollutants, asbestos, etc.), bacterial, fungal or viral
infections and radiation. Exercise has the potential to induce free radical formation
leading to OS [31]. Much of the damage associated with cocaine toxicity stems from OS
[32]. In addition to environmental and lifestyle exposures, the determinants of oxidative
stress are regulated by hereditary factors. Oxidative stress is also implicated in the
ischemic cascade in reperfusion injuries. Myoglobin from myolysis, common with
syndromes like rhabdomyolysis, may cause OS [33]. ROS are not uniformly destructive;
they are used by the immune system as a way to attack and kill pathogens and in redox
signaling.
Cocaine (benzoylmethylecgonine) is an alkaloid derived from the leaves of
Erthroxylon coca, a shrub indigenous to South America [34]. Despite restrictions on
importation and distribution, cocaine has become one of the most commonly used illicit
drugs [35]. According to the 2007 National Survey on Drug Use and Health, nearly 1.6
million Americans met Diagnostic and Statistical Manual of Mental Disorders criteria for
dependence or abuse of cocaine (in any form) in the past 12 months. The 2005 Drug
Abuse Warning Network (DAWN) report stated that cocaine was involved in 448,481 of
the total 1,449,154 (31%) visits to emergency departments (ED) for drug misuse or
abuse. Cocaine is the most frequently reported illicit drug associated with ED admissions
[36]. Cocaine is a powerful sympathomimetic capable of vasoconstriction and increasing
heart rate, blood pressure, contractility, respiration, myocardial oxygen demand and body
temperature [37]. Hyperpyrexia can lead to rhabdomyolysis, myoglobulinuria, renal
failure, liver damage and disseminated intravascular coagulation [38]. Cocaine use is
7

linked to atherosclerosis, myocardial ischemia, myocardial contraction band formation
and sudden death [36, 39]. Cocaine-induced chest pain is the most common symptom
reported by patients; an estimated 64,000 patients were evaluated for myocardial
ischemia in 1995 subsequent to cocaine-related chest pain [40, 41]. Some of these
patients exhibited elevated CK-MB levels or electrocardiogram (ECG) changes
consistent with acute myocardial infarction (AMI); however, the majority reported
recurrent chest pain subsequent to cocaine use following discharge [41, 42].
The metabolism of cocaine is primarily hepatic, with only about 1% excreted
unchanged in the urine [43]. Cocaine has two primary metabolic pathways in humans,
deesterification and demethylation. Benzoylecgonine (BE) is the primary metabolite and
is not considered an important source of ROS. Ecgonine methyl ester (EME) is the
second most common metabolite. Neither BE nor EME are biologically active.
Transmethylation of cocaine is a minor pathway; metabolites of this pathway include
norcocaine, norcocaine nitroxide, n-hydroxynorcocaine and formaldehyde. Microsomes
in the brain and liver oxidize norcocaine to nitroxide. Microsomal reduction of
norcocaine nitroxide in the brain generates superoxide (SO) [32]. Hepatic microsomes
incubated with nitroxide or the N-hydroxy derivative results in lipid peroxidation [27].
Transesterification of cocaine occurs in the presence of alcohol and produces the
biologically active intermediate cocaethylene. Various cocaine related hepatotoxicity
studies indicate the generation of ROS, including lipid peroxides [44, 45]. Cocaine has
been shown to induce the release of SO which has been implicated in cardiac and
cerebrovascular dysfunction [32].
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The vasoconstriction associated with cocaine usage is thought to result from its
blockade of norepinephrine and dopamine reuptake at preganglionic sympathetic nerve
endings; the extended catecholamine presence increases heart rate and blood pressure
[40, 46]. Cocaine also disrupts catecholamine metabolism by inhibiting monoamine
oxidase (MAO). By blocking the neuronal plasma membrane transporter, cocaine
increases extracellular levels of monoamines [47]. Hypertension is associated with
disruptions in endothelial cell function and oxidative stress. MPO promotes endothelial
dysfunction [48]. Microalbumin is inducible by endothelial dysfunction and oxidative
stress; cocaine use may impact expression of this marker [49]. IL1α and IL1β are induced
by increased body temperature [50]. Cocaine is a known hyperpyrexic so it is possible
that usage could result in increases in the concentrations of these markers [51]. Oxidative
stress has also been implicated as an early triggering event of cocaine-induced
cardiomyopathy and atherosclerosis [52] . IL6, CRP and MPO are being considered for
validation as cardiac biomarkers [48, 53]. MPO has also been linked to the pathogenesis
of renal injury [54, 55]. Increased expression of these cytokines may result from cocaineinduced atherosclerosis and other cardiac disruptions. Fluctuations in blood pressure
activate the renin-angiotensin system RAS which may increase proANP expression along
with aldosterone production. RAS activation contributes to OS and vascular
inflammation; it can also change the baseline filtering activity of the kidneys.
Aldosterone stimulates inflammation through ROS generation. Cocaine use is linked to
both renal dysfunction and rhabdomyolysis [34, 56]. NGAL is a validated marker for
acute kidney damage and inflammatory processes [57]. Myoglobinuria, proteinuria and
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increased expression of creatinine are associated with rhabdomyolysis and cardiac
dysfunction; both conditions may result from cocaine use [53, 58].
The link between biomarker expression in urine and gender or cocaine-based
inflammation, cardiac damage, or other systemic injury has not been elucidated. Urine
samples were assayed for benzoylecgonine (BE), total protein, aldosterone, c-reactive
protein (CRP), myeloperoxidase (MPO), microalbumin (MAB), neutrophil gelatinaseassociated lipocalin (NGAL), heat shock protein 90α (hsp90α), vascular endothelial
growth factor (VEGF), myoglobin, pro atrial natriuretic peptide (proANP) and
interleukins 1α, 1 β, and 6 using ELISA and colorimetric assays; these markers were
selected for their biological plausibility and assay kit availability. Urine is a non invasive
specimen typically provided in sufficient quantity to allow multiple tests. As most
toxicological screens primarily utilize urine specimens in clinical settings, we examined
the possibility of establishing relationships between the expression of several urinary
biomarkers associated with oxidative stress and inflammation and gender and cocaine
use.
The following hypotheses were tested in this study:
1. The expression of some urinary markers of inflammation and/or oxidative stress is
influenced by gender. Creatinine and myoglobin are related to lean muscle mass;
therefore, males should have higher urinary mean concentrations. Total protein,
microalbumin and NGAL may be elevated in females as they suffer far more urinary tract
infections than males. IL1α, IL1β, IL6, MPO, VEGF and CRP may be higher in females
as they suffer disproportionately from autoimmune/inflammatory diseases.
10

2. The expression of these markers is influenced by the use of cocaine. Creatinine and
myoglobin are increased by hyperthermia and rhabdomyolysis; therefore, cocaine
positive specimens should have a higher mean values than control urine specimens.
Cocaine induces oxidative stress and inflammation; aldosterone, myoglobin, VEGF,
NGAL, IL1α, IL1β, IL6, MPO and CRP may be higher in cocaine positive specimens.
Hsp90α and proANP are associated with cardiac dysfunction; they may be higher in
cocaine positive specimens.

11

Chapter 2.0
Literature Review

2.1 Gender

There are significant gender based differences in the etiology of disease states
including cardiac and vascular disease, metabolic disorders, autoimmune disorders and
drug abuse toxicology. The basis of the gender dimorphism is unclear; however, cardiac
muscle and vascular tissue are influenced by hormones such as estrogen and testosterone
[1, 9, 10, 12, 59-61]. Premenopausal women appear to be partially protected to some
extent from cardiovascular and kidney diseases; however, this protection weakens after
menopause [62]. Gender differences may exist not only in atherogenesis but also in post
ischemic/infarction cardiovascular repair. Angiogenesis is essential to cardiovascular
repair and regeneration. The effect of estrogen on angiogenesis has been extensively
studied, but the role of androgens remains unexplored [63]. Estrogens induce vasodilation
by increasing the activity of endothelial nitric oxide synthase (eNOS).

Estrogens and androgens regulate the RAS which in turn regulates the
cardiovascular system and the kidneys [64]. In general, estrogen decreases renin
12

production thereby decreasing aldosterone production. Progesterone competes with
aldosterone for mineralocorticoid receptor. Aldosterone is linked to inflammation via
ROS generated oxidative stress. Aldosterone is a renal hormone in the RAS secreted in
response to hypotension. Aldosterone has been implicated in renal disease progression;
the majority of renal diseases are far more common in men. Increased cardiac
concentrations have been linked to heart failure. Creatinine is also a general marker of
muscle and kidney disease [18, 19]. Because creatinine is related to lean muscle mass,
men tend to have slightly higher serum creatinine levels than do women. Increased
vascular oxidative stress leads to endothelial dysfunction and hypertension. Inhibition of
the RAS results in a decline in ROS production [65, 66]. Estrogen also activates
natriuretic peptides such as proANP; these peptides are a counterpart of the RAS.
Testosterone seems to exert the opposite effect on renin levels. These effects of sex
hormones on the RAS may explain some of the gender differences in cardiovascular and
kidney diseases [67].

Exposure to sex hormones modulates many endocrine factors involved in
atherosclerosis. Increased vascular oxidative stress leads to endothelial dysfunction and
hypertension. It has been noted that inhibition of the RAS results in a decline in ROS
production [65, 66]. Studies suggest females are at lower risk of developing
cardiovascular disease (CVD) as compared to males [68]. Striking sex differences exist
not only in the incidence of cardiovascular disease, but also in the clinical outcomes.
Cardiovascular events occur earlier in men than in women; however, it appears women
have poorer short-term and long-term outcomes following these events compared to men.
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Autoimmune disorders may contribute to the gender based differences in cardiac
outcomes; for example, RA, far more common in women, is associated with a higher
prevalence and higher severity of atherosclerosis [69].

Autoimmune diseases are the third most common category of disease in the
United States after cancer and heart disease. Male and female immune response differs;
women mount more vigorous immune responses with increased antibody production
[70]. Women also have far higher autoimmune disease rates [71, 72]. When men develop
autoimmune diseases, they are often more severe. Many animal models of autoimmune
disease have shown a similar sex bias, with a higher incidence of disease in females [7377]. Estrogen, testosterone, and progesterone are thought to mediate most of the sexbiased differences in the immune response [78, 79]. Cytokine receptors such as
interleukin 1 receptor (IL-1R) have been discovered on hormone-producing tissues.
Proinflammatory cytokines such as IL-1α and IL-1β stimulate the release of
glucocorticoids which regulates the inflammatory process along with androgens and
estrogens. Estrogen significantly increases proinflammatory cytokine production of IL1α, IL-1β and IL-6. [6, 27, 29, 30, 80-82]. Interleukins act specifically as mediators
between leukocytes. Activated leukocytes can generate ROS, which contributes to
hypertension and atherosclerosis [83]. Many autoimmune disorders are strongly
associated with cardiac and metabolic disorders.

Women tend to have slightly higher serum CRP than men with the same body
mass index (BMI) and age; however, these differences are not pronounced enough to
warrant gender-dependent reference ranges [84, 85] . The role of gender in predisposition
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to oxidative stress has yet to be determined. CRP is an acute phase inflammatory marker
considered to be a reliable prognostic indicator of atherosclerosis and acute myocardial
infarction (AMI) [61, 82, 86]. Urinary levels peak approximately 24 hours following the
inflammatory event and are undetectable within 13 to 16 hours. As a measure of
leukocyte infiltration, MPO is an inflammatory marker used to predict the risk of AMI in
the absence of cardiac necrosis [54, 87]. The predictive value of this marker has not been
fully characterized; however, it is associated with long term adverse cardiac events. E2
has been suggested as a potential endogenous substrate for MPO in plasma [88].
Recognition and elaboration of the innate differences of gender physiology may result in
better treatment adaptations for women and better outcomes [89].

2.2 Inflammation

Inflammation can be classified as either acute or chronic. Acute inflammation is
the initial response to harmful stimuli and is achieved by mobilization of plasma and
leukocytes, particularly granulocytes, from the blood into the injured tissues. It is
characterized by vasodilation, increased permeability and reduced blood flow; these
changes are induced by multiple inflammatory mediators [90]. Trauma, inflammation, or
infection leads to the activation of the inflammatory cascade. A progression of
biochemical events, including components of the local vasculature, the immune system,
and various cells triggers the inflammatory response. Unlike acute inflammation, chronic
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inflammation is mediated by cells such as monocytes and lymphocytes. Chronic
inflammation leads to a progressive shift in the type of cells present at the site of
inflammation and is characterized by simultaneous destruction and healing of the tissue
from the inflammatory process [91].
Tissue macrophages, monocytes, mast cells, platelets, and endothelial cells are
able to produce a multitude of cytokines. The release of as IL-1α and IL-1β leads to
cleavage of the nuclear factor-kB (NF-kB) inhibitor. Removal of the inhibitor allows NFkB to initiate mRNA production, thereby inducing production of other proinflammatory
cytokines like IL-6. IL-1 is responsible for fever and the release of stress hormones
(norepinephrine, vasopressin, activation of the renin-angiotensin-aldosterone system).
Cytokines like IL-6 stimulate the release of acute-phase reactants such as CRP. Infection
has been shown to elicit a stronger response than trauma, which translates to a greater
release of IL-6. Estrogen has been shown to directly inhibit IL-6 production [92].
Inflammation is a highly regulated process that recruits the immune system to
sites of infection and injury and to facilitate tissue repair processes. Prolonged
inflammation produces local and systemic damage associated with a loss of normal
physiological functions. Activation of proinflammatory cytokines results in
vasodilatation, release of cytotoxic compounds like MPO, generation of ROS and
damage to the vasculature. Proinflammatory cytokines like IL-1α, IL-1β and IL-6
upregulate endothelial enzyme expression which plays an important role in atherogenesis.
Some autoimmune diseases, such as RA, SLE and Sjogren's syndrome, are characterized
by chronic inflammation.
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Chronic inflammation is a crucial element in the development of multiple disease
processes, including renal dysfunction, cardiovascular disease, autoimmune disorders,
cancer and DM [53, 91]. Assessment of inflammatory markers like CRP, MPO and the
interleukins can lead to improved risk stratification in disease. Estrogen and testosterone
can affect the expression of proinflammatory markers in macrophages. Testosterone may
reduce the expression and secretion of IL-1β, but it does not appear to affect the
expression of IL-6 or CRP. Estrogen elicits a variable response in CRP expression [93].
Aldosterone causes tissue inflammation; this may result in fibrosis and
remodeling in the heart, vasculature, and kidney [94]. Aldosterone triggers endothelial
cell exocytosis, which is a crucial step in leukocyte mobilization [95]. During active
inflammatory disease such as Crohn‟s disease or RA, metabolic shifts may cause in
hypoxia in affected membranes. Activation of hypoxia-inducible factor (HIF) subsequent
to hypoxia has been shown to upregulate production of hsp90α and VEGF [96]. VEGF
increases endothelial permeability and is associated with microalbuminuria and
myoglobinuria [97].

2.3 Oxidative stress

Oxidative stress is determined by the balance between the rate at which oxidative
damage in a cell, tissue, or organ is induced and the rate at which it is repaired or
removed. Inactivation of ROS by endogenous antioxidants like superoxide dismutase and
17

glutathione peroxidase determines the rate at which damage is induced [67, 98]. Repair
enzymes determine the rate at which damage is repaired. Most ROS come from the
endogenous sources as by-products of normal and essential metabolic reactions.
Lifestyle and environmental exposures also contribute to ROS. While there are many
biomarkers of inflammation, oxidative stress is difficult to measure in vivo. Traditional
indices of oxidative stress include markers of oxidative damage to lipids, proteins and
DNA. Oxidative stress is also indirectly assessed by measuring markers of inflammation
such as MPO[99].
ROS include free radicals and peroxides such as hydrogen peroxide,
hypochlorous acid and peroxynitrite. When converted by oxidoreduction reactions,
superoxide can be transformed into more aggressive radical species capable of causing
extensive cellular damage. Long term effects of ROS exposure can include damage to
DNA. Oxidative stress is implicated in diseases such as atherosclerosis, Parkinson's
disease, heart failure, myocardial infarction, Alzheimer's disease, fragile X syndrome and
chronic fatigue syndrome. Oxidative stress is linked to certain cardiovascular diseases;
oxidation of low density lipoprotein in the vascular endothelium is a precursor of
atherosclerotic plaque formation. Oxidative stress plays a role in the ischemic cascade
due to oxygen reperfusion injury following hypoxia. It is also associated with the
detrimental effects of aging.
Aging induces a pro-inflammatory state characterized by increasing levels of
inflammatory cytokines such as IL-1α, IL-1β and IL-6 [100, 101]. Aging is associated
with a declining serum testosterone levels. Studies suggest a close relationship exists
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between the development of a pro-inflammatory state and the decline in testosterone
levels, two trends that are often observed in aging men. Additionally, E2 is weakly
associated with IL-6 in older men, independent of testosterone.
Myoglobin is a molecular radical scavenger activated by ischemia and myolysis;
serum and urine myoglobin concentrations increase with OS [33, 102]. Creatinine
concentrations are associated with muscle mass. Activity of creatinine and myoglobin
correlate to stress induced neutrophil response common in exertional and injury induced
rhabdomyolysis [103]. Aldosterone is linked to generation of ROS and the induction of
oxidative stress [104, 105]. Atrial natriuretic peptide (ANP) is a hormone, primarily
produced by cardiomyocytes, which regulates blood pressure. Studies have linked ANP
with the generation of ROS. ANP may produce either antioxidant or prooxidant effects,
depending on experimental conditions and cell context [106].
ROS generation occurs in hepatocytes and in the respiratory burst of Kupffer
cells, triggering a proinflammatory cascade upregulating multiple interleukins. Specific
receptors in hepatocytes stimulate the expression of antioxidant enzymes such as
manganese superoxide dismutase and acute-phase proteins. These responses help protect
the liver against ischemia-reperfusion injury[107]. OS plays an important role in
pathogenesis of hepatic diseases like alcoholic liver injury. Cardiac surgery-associated
acute kidney injury (AKI) is common and is associated with increased expression of
NGAL [105]. Increased OS is considered a causative factor of DM, particularly diabetic
cardiovascular and renal sequelae. Hyperglycemia is thought to induce the
overproduction of ROS. Oxidative stress is also a factor in the pathogenesis of
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hypertension and target organ damage, largely due to its effects on the vasculature.
Oxidative metabolites of cocaine generate significant ROS; much of the
pathophysiological damage associated with cocaine use stems from oxidative stress and
electron transfer[32].

2.4 Cocaine

Cocaine, C17H21NO4, is a potent cardiac and central nervous system stimulant. It
is fat soluble and freely crosses the blood-brain barrier. Cocaine is rapidly hydrolyzed by
serum cholinesterase in plasma and carboxylesterases in the liver following use; the
primary metabolites are BE and EME (Figure 2). Lesser metabolites include
cocaethylene (CE), norcocaine and anhydrous ecgonine methyl ester (only seen in crack
cocaine use). Cocaine and ethanol are independently cardiotoxic; together they exhibit
synergistic cardiotoxicity. In the presence of alcohol, a nonspecific carboxylesterase
catalyzes ethyl transesterification of cocaine to CE. Animal studies have demonstrated
that co-administration results in prolonged cardiac toxicity and dysrhythmias [108]. It has
also been demonstrated that ED patients with detectable CE concentrations are more
likely to be admitted to intensive care units than those patients testing negative for CE
[109]. The half-lives of cocaine, CE and BE are 40 minutes, 2.5 hours and 5 to 8 hours
respectively. This may explain why cocaine-related symptoms can continue for some
time after cocaine is last used. Cocaine has only one biologically active metabolite,
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norcocaine. The oxidative metabolism of cocaine to norcocaine nitroxide is postulated to
be essential for cocaine hepatotoxicity [110].
Cocaine induces local vasoconstriction and an anesthetic effect by inhibiting fast
sodium channels. Cocaine is a strong sympathomimetic that blocks catecholamine
reuptake, effectively flooding the synaptic space with norepinephrine thereby stimulating
the central and peripheral nervous systems [56]. The effect of cocaine is especially
pronounced in the limbic system where it potentiates dopaminergic transmission in the

Figure 2. Metabolites of Cocaine
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ventral basal nuclei. The potentiation of dopamine is responsible for the pleasurable
behavioral effects that make cocaine a popular drug of abuse. Cocaine causes moderate
release and reuptake-blockade of serotonin and dopamine [111-113]. Cocaine-induced
hyperpyrexia, a potentially fatal elevation in body temperature exceeding 41° C, is
thought to be associated with dopamine receptor blockade in the temperature regulation
region of the hypothalamus. The sodium channel blockade decreases the resting
membrane potential and action potential amplitude while simultaneously prolonging the
duration of the action potential. Cocaine also blocks potassium channels. In some cellular
membranes, it may block sodium-calcium exchange.
Almost every organ system is affected by cocaine use. Myocardial infarction,
arrhythmias, renal failure, hypertension, atherosclerosis, and rhabdomyolysis are all in
the spectrum of acute and chronic cocaine toxicity [114, 115]. Cocaine is associated with
an increased vascular risk; the brain, heart, kidney, liver and lungs are all susceptible to
its vasculotoxicity. It can cause abrupt changes in blood pressure, embolism via infective
endocarditis, and hemostatic and hematologic abnormalities that can result in increased
blood viscosity and platelet aggregation. Most ED patients with cocaine-associated chest
pain have normal cardiac profiles at the time of presentation. The negative inotropic
effects of cocaine observed in animal models do not appear to be present in patients who
develop chest pain after using recreational doses of cocaine [116].
Cocaine is known to have specific, dose-dependent effects on brain and body
temperatures, these effects are strongly modulated by an individual's activity state and
environmental conditions, and change dramatically during the development of drug self22

administration. Environmental conditions potentiate the thermal effects of cocaine which
may result in pathological brain overheating. Hyperthermia can exaggerate the toxicity of
cocaine; environmental conditions that impair heat loss can result in acute lifethreatening complications and chronic destructive CNS changes [117]. Deleterious
effects of hyperthermia include activation stress response systems, decreased immune
efficiency, increased blood viscosity, vasoconstriction, renal and hepatic insufficiency
and rhabdomyolysis.
Rhabdomyolysis is a disorder in which injury to muscle results in leakage of
myocyte intracellular contents into the plasma. Dissolution of muscle fibers and leakage
of muscle enzymes, myoglobin, potassium, calcium, and other intracellular constituents,
can occur. For this reason, myoglobinuria and albuminuria are common clinical markers
of rhabdomyolysis. Serum proinflammatory and inflammatory cytokines like IL-1α, IL1β, MPO and CRP are similarly elevated. Cocaine has been shown to diminish IL-6
response to proinflammatory challenges [118]. IL-6 is a multifunctional cytokine
implicated in many age-related diseases, including postmenopausal osteoporosis and
Alzheimer‟s disease [119]. The most likely etiology of rhabdomyolysis in patients
presenting to the emergency department is ingestion of drugs of abuse such as cocaine
[58]. The hemodynamic actions of cocaine contribute to renal injury. Cocaine abuse has
been linked with acute renal failure and acid-base and/or electrolyte disorders and may
trigger the progression of chronic renal failure to end-stage renal disease.
Cocaine use is associated with frontal cortex and glial injury in both frontal gray
and white matter. Women showed equivalent responses to drug administration with the
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exception of the limbic system; their perception of well-being was significantly increased
[120]. These findings may have implications for differential risk for acute and chronic
toxicity in women. Some animal studies suggest estradiol increases sensitivity of the
brain reward system [121].Progesterone may enhance cocaine craving and relapse
susceptibility in women [122]. Research also suggests adolescents are more sensitive than
adults to interactions between testosterone and cocaine [123].
There are significant gaps in the literature that make it difficult to define the
relationship between gender and cocaine. Social parameters have been described; males
are more likely than females to use cocaine and males tend to use cocaine at an earlier
age than do females. The pathophysiological gender based differences cannot be
elaborated until study populations begin to include females. The bulk of research
performed in recent years has focused on psychosocial and neurobiological differences
between cocaine using females and males [124-126]. Given the stark physical contrasts
between the genders, particularly in immune response and autoimmunity, the focus may
need to be widened to include gender based differences in the inflammatory and
oxidative response to cocaine use.
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Chapter 3.0
Materials and Methods

The Agency for Community Testing Services (ACTS) Laboratories provided
urine specimens with all information blinded apart from gender, creatinine and the results
of the NIDA 10 drug screen. 41 specimens were donated by males, 39 specimens by
females. 40 specimens tested negative to all substances on the NIDA 10 panel (THC,
opiates, amphetamines, barbiturates, cocaine, ethanol, benzodiazepines, propoxyphene,
methadone and oxycodone) and 40 specimens tested positive for cocaine metabolites
alone. Limited demographic information was available for some of the donors; for
example, age was available for 66 of the donors. The donors‟ ages ranged from 16 to 62;
the mean donor age was 34 years old. Donor weight was available for 46 of the 80
donors. The female weights ranged from 113 to 327 lbs and the mean female donor
weight was 162.5 lbs. The male weights ranged from 120 to 240 lbs and the mean male
donor weight was 166.6 lbs.
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Table 1. Summary of Assays Performed
Analyte

Method

Manufacturer

Total Protein

Colorimetric

Pierce

Creatinine

Colorimetric

Cayman

Cocaine/Benzoylecgonine (BE)

ELISA

Immunalysis

Aldosterone

ELISA

ALPCO

C Reactive Protein (CRP)

ELISA

ALPCO

Myeloperoxidase (MPO)

ELISA

ALPCO

Microalbumin (MAB)

ELISA

ALPCO

Myoglobin (MGB)

ELISA

Life Diagnostics

Heat Shock Protein 90α (hsp90α)

ELISA

Assay Designs

Vascular Endothelial Growth Factor
(VEGF)

ELISA

Raybiotech

Neutrophil Gelatinase Associated
Lipocalin (NGAL)

ELISA

Quantikine

Pro Atrial Natriuretic Peptide
(proANP)

ELISA

ALPCO

Interleukin 1α (IL 1α)

ELISA

Cayman

Interleukin 1β (IL1β)

ELISA

Cayman

Interleukin 6

ELISA

Cayman
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3.1 EMIT

Enzyme Multiplied Immunoassay Technique (EMIT) is a common method for
screening urine and blood for drugs, legal and illicit. This inexpensive technique is fast,
relatively sensitive and specific, and has been adapted to various automated analyzers.
The non-linear relationship between the change in absorbance and analyte/drug
concentration in the specimen is the reason the assay is only useful for qualitative
determinations. Results are expressed as Δ absorbance (M) units and compared with
results for cutoff-value calibrators to indicate a positive or negative result. This
qualitative procedure may be followed with confirmatory (quantitative) GC/MS testing as
necessary.
An EMIT drug test contains antibodies that target specific drugs in the urine
specimen. If an antibody does not become attached to the drug in the urine specimens, it
attaches itself to the chemically tagged drug in the EMIT reagent. ACTS uses
DRI/Microgenics (Thermo Fisher Scientific Corporation, Waltham, MA 02454) reagents
and controls for the NIDA 10 EMIT panel. The NIDA 10 panel consists of Cocaine
(COC), Amphetamine (AMP), Methamphetamine (M-AMP), Tetrahydrocannabinol
(THC), Methadone (MTD), Opiates (OPI), Phencyclidine (PCP), Barbiturates (BAR),
Benzodiazepines (BZD) and Oxycodone (OXY) in human urine. Chemically tagged
drugs without an attached antibody (i.e. the reagent) are transformed by a reaction that
changes the absorbance of the test sample. Attachment of an antibody inhibits this
reaction. The Olympus AU640e Chemistry ImmunoAnalyzer (OLYMPUS America Inc.,
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Center Valley, PA 18034-0610) used by ACTS Laboratory measures the changes in
absorbance in the test sample; the change in absorbance is then compared to the
absorbance of the calibrators. If the absorbance of the test sample is equal to or exceeds
the calibrator‟s, the specimen is considered positive for the drug in question. Conversely,
if the absorbance of the test sample is less than that of the calibrator, the specimen is
considered negative for the drug.
In 1988, the American Association for Clinical Chemistry (AACC) conducted a
study of the testing accuracy of laboratories with regard to drugs of abuse. This study was
blinded and used cutoff concentrations very close to the guidelines of the Substance
Abuse and Mental Health Services Administration (SAMHSA). Their overall accuracy
rate was 97%. There were a small number of false negative results (2–4%) on samples
with drug concentrations close to the cutoff. There were no false positive results.

Components of the EMIT Assay Method (Figure 3):
1. Drug
2. Antibody
3. Substrate
4. Drug enzyme complex

28

Figure 3. EMIT Assay Components in Action

3.1.1 General Procedure for EMIT Assay
1. Mix sample containing drug with fixed quantity of enzyme bound drug, and
antibody
2. Add substrate
3. Measure absorbance at 15 and 45 seconds after substrate addition
4. Quantitate by measuring enzyme-substrate reaction (by UV - visible
spectroscopy)
5. Δ Absorbance from Reaction rate from Drug concentration
6. Non linear relationship between Δ Absorbance and Concentration
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7. Determine standard curve

ACTS laboratory uses the Olympus AU640e for drugs of abuse analysis (Figure
4). The analyzer screens urine specimens for the NIDA 10 panel of drugs. The cocaine
test analyzes urine specimens for the presence of the primary cocaine metabolite,
benzoylecgonine, rather than the parent compound (cocaine). As previously stated, EMIT
does not measure the amount of the drug present; it simply detects its presence or absence
as determined by an established cut-off level. The drug in the manufacturer‟s reagent is
labeled with an enzyme such as glucose-6-phosphate dehydrogenase (G6PDH). The
enzyme-ligand-antibody complex is inactive thereby allowing determination of unlabeled
ligand.
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Figure 4. Olympus AU640e Chemistry-Immuno Analyzer

3.1.2 Cocaine/Benzoylecgonine
3.1.2.1 General Principle of the Assay
The DRI Cocaine Metabolite Assay used (DRI Cocaine Metabolite Assay #0056,
Microgenics Corporation Fremont, CA 94538) by ACTS Laboratory is intended for the
qualitative and semiquantitative determination of benzoylecgonine in human urine. This
assay provides only a preliminary analytical test result. Quantitative determination
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requires alternative methods; gas chromatography/mass spectrometry (GC/MS) is the
preferred confirmatory method.
The DRI Cocaine Metabolite Assay is a homogeneous enzyme immunoassay
using ready-to-use liquid reagents. The assay uses a specific antibody to detect
benzoylecgonine in urine specimens. The assay is based on the competition of an enzyme
glucose-6-phosphate dehydrogenase (G6PDH) labeled BE and any BE from the urine
sample for a finite number of specific antibody binding sites. In the absence of BE in the
sample, the specific antibody binds to the G6PDH labeled BE and the enzyme activity is
inhibited. This means there is a direct relationship between the BE concentration in the
urine and the enzyme activity. The enzyme G6PDH activity is determined by measuring
its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH
spectrophotometrically at 340nm using the lab‟s Olympus AU640e Chemistry-Immuno
Analyzer.

3.1.2.2 Specificity
Benzoylecgonine, cocaine and other compounds that are concurrently present in
the urine were tested for cross- reactivity in the assay. Cocaine and EME are the only
compounds that demonstrated crossreactivity. Urine specimens arrive in sterile containers
from a number of remote collection sites, including jails, hospitals and medical offices.
Possible adulteration of urine specimens is an important consideration for drug testing
facilities. Accordingly, samples undergo several tests to determine the likelihood of
adulteration. Color and odor are assessed for evidence of adulteration, either by dilution
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or the addition of an oxidant such as bleach. The tests used to check for adulteration
include creatinine concentration, pH and specific gravity. Urine specimens with values
outside normal reference ranges are discarded.
The reference ranges for:


Urine creatinine is 25-350 mg/dL



Urine pH is 5.0 to 6.5



Urine specific gravity is 1.003 to 1.030

Dilution of the specimen may result in abnormal lows for one or more of the
markers. In some instances the specimens are highly concentrated and dilution may make
creatinine levels normal. Substitution with a liquid other than urine will be revealed by
the absence of creatinine. Commercial masking agents may include components such as
glutaraldehyde to interfere with the drug screen; for this reason, nitrites levels are
occasionally used to establish the legitimacy of a specimen. This is not foolproof as
bacterial infection and contamination may increase urine nitrite levels.

3.1.3 Creatinine
Creatinine is routinely included in urinary analysis as a control for dilute or
adulterated specimens. It is a metabolic by-product of creatine degradation in muscle
tissue. Most methods for determining the creatinine concentration of a specimen, in urine
33

or serum, rely on the Jaffe reaction in which creatinine reacts with alkaline picrate to
form a red-yellow solution that is then measured photometrically (Figure 5).

NaOH
Creatinine + Picric Acid  Janovski Complex
Figure 5. Modified Jaffe Reaction

Since urine contains other substances which can react with picrate, the Olympus
uses reagents from Microgenics for a modified version of the Jaffe reaction with
improved specificity. The color intensity of the creatinine-picric acid complex is directly
proportional to the concentration of creatinine in the urine specimen and is measured
spectrophotometrically at 505 nm. Each laboratory establishes its own reference range
for creatinine levels but they average from 25 to 300 mg/dL. When the value obtained
exceeds 300 mg/dL, the specimen should be diluted with physiological saline and reassayed. The established cutoff value for creatinine is 20 mg/dL and the assay is said to
be linear to 400 mg/dL.

3.1.4 Specific Gravity
Specific gravity simply refers to the dissolved solutes present in urine as
compared to the value set by convention, for pure water (1.000). Values obtained for
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specific gravity are affected by the number, size and weight of molecules in urine. For
this reason, it is considered an approximation of solute concentration. The urine specific
gravity assay relies upon the use of a linear relationship between urinary chloride ion
concentration and measured specific gravity. Determination of the chloride ion is
colorimetric; in an aqueous medium, ferric perchlorate and chloride ion form a ferrous
chloride complex that has an absorbance maximum of 340 nm (Figure 6). Absorbance at
340 nm is directly proportional to concentration of chloride ion in the specimen. Urine
specific gravity is extrapolated from this value.

Cl- + Fe 3+  FeCl2+
Figure 6. Urine Specific Gravity Reaction Equation

3.1.5 Ethanol
The ethanol assay is based on the high specificity of alcohol dehydrogenase
(ADH) for ethyl alcohol. In the presence of ADH and nicotinamide adenine dinucleotide
(NAD), ethanol is readily oxidized to acetaldehyde and NADH (Figure 7). The
enzymatic reaction is monitored spectrophotometrically at 340nm. The ethanol in the
sample is in direct proportion to the rate of change of absorbance at 340 nm.
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Figure 7. Oxidation of Ethanol to Acetaldehyde

3.2 Colorimetric Analysis
Colorimetry relies on colored solutions absorbing light of a particular wavelength;
however the technique can also be used to analyze colorless substances if they react with
a dye. The TECAN M200 Infinite Microplate Reader (TECAN US Inc., Durham NC
27703) can be used for simple colorimetric analyses such as the creatinine assay and total
protein assessment. The absorbance of the urine specimens is determined by comparing
them to a calibration curve generated from known standards.
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3.2.1 Total Protein
3.2.1.1 General Principle of Assay
The Coomassie Protein Assay kit used (Coomassie Protein Assay Kit #23200,
Pierce Biotechnology, Rockford, IL 61105) is a typical colorimetric assay. The Pierce
Coomassie Protein reagent is a modification of the Bradford Coomassie Dye-protein
binding colorimetric method of protein quantitation. When Coomassie dye binds to
protein in an acidic medium, the color in the wells changes from brown to blue as the
absorbance maximum shifts.
A 5 μl aliquot of standard, control urine or cocaine positive (as previously
determined by EMIT) urine specimen is incubated with a 250 μl of Coomassie Reagent in
micro-plate wells for 10 minutes. The plate is read at 595 nm to obtain the absorbance. 5
μl of acid is then added to the wells. The absorbance is directly proportional to the
concentration of protein in the sample. A set of standards is used to plot a standard curve
from which the amount of total protein in samples and controls can be directly read.

3.2.1.2 Assay Procedural Details
Kit Contents:
1. Coomassie Protein Assay Reagent ready to use
2. Albumin Standard Ampules 2mg/ml requires serial dilution
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Phosphate Buffered Saline (PBS) is the diluent chosen for the assay. PBS is a commonly
used isotonic buffer solution in biological research. The osmolarity and ion
concentrations of the solution usually match those of the human body fluids. The 1x PBS
stock solution used for the Total Protein Assay was prepared by dissolving 8.00 g of
NaCl, 0.20 g of KCl, 1.44 g of Na2HPO4 and 0.24 g of KH2PO4 in 800 ml of Barnstead
Nanopure Water. If necessary, the pH can be calibrated to 7.4 with the addition of HCl or
NaOH. The final volume is adjusted to 1 liter with additional Barnstead Nanopure Water.

The albumin standards were prepared as described in the table below (Table 2):
Table 2. Concentration of Albumin Standards
Volume of Diluent
(μl)

Tube

Volume and Source of BSA
(μl)

Final
Concentration
(μl /ml protein)

A

0

300 of stock

2000

B

125

375 of stock

1500

C

325

325 of stock

1000

D

175

175 of tube B

750

E

325

325 of tube C

500

F

325

325 of tube E

250

G

325

325 of tube F

125

H

400

100 of tube G

25

I

400

0

0 (blank)
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All reagents must reach room temperature before use. Mix the Coomassie
Reagent immediately prior to use by gently inverting the bottle several times. Calibrators,
controls and specimen samples should be assayed in duplicate. Once the procedure has
been started, all steps should be completed without interruption.
5 μl of each standard, control urine and cocaine positive urine were pipetted into
correspondingly labeled wells in duplicate. Next, 250 μl of the Coomassie Reagent was
pipetted into each well. The plate was incubated on a plate shaker (approximately 200
rpm) for 10 minutes at room temperature. The plate was read at 595 nm to calculate the
absorbance. A standard curve was produced and the concentration of protein in each of
the specimens was determined from the blank- adjusted absorbance.

3.2.1.3 Interfering Substances
Most ionic and nonionic detergents

3.2.2 Creatinine
3.2.2.1 General Principle of Assay
The Creatinine kit used (Creatinine Assay Kit #500701, Cayman Chemical
Company, Ann Arbor, MI 48108) is a typical colorimetric assay. It is not appropriate for
diagnostic use. It relies on the Jaffe‟ reaction; in Jaffe‟, a yellow/orange color is formed
when the metabolite is exposed to alkaline picrate. The color derived from creatinine is
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destroyed at acidic pH. The difference in the color before and after acidification is
measured at 500 nm and is proportional to the creatinine concentration in the urine
specimen.
A 15 μl aliquot of a diluted standard, control urine or cocaine positive (as
previously determined by EMIT) urine specimen is incubated with a 150 μl of Alkaline
Picrate Solution in micro-plate wells for 10 minutes. The plate is read at 500 nm; the
value obtained is the Initial Absorbance. 5 μl of acid is then added to the wells. After
incubating for 20 minutes, the Final Absorbance is obtained by reading the plate at 500
nm. The difference between the initial and final absorbance is directly proportional to the
concentration of creatinine in the sample. A set of standards is used to plot a standard
curve from which the amount of creatinine in samples and controls can be directly read.
The dynamic range of the Cayman Creatinine assay is 0 – 15 mg/dl.

3.2.2.2 Assay Procedural Details
Kit Contents:
1. Creatinine Standard requires dilution
2. Creatinine Color Reagent (1.2% picric acid) ready to use
3. Creatinine Sodium Hydroxide (0.1M NaOH) ready to use
4. Creatinine Acid Solution ready to use
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5. Creatinine Sodium Borate ready to use
6. Creatinine Surfactant ready to use

To prepare Alkaline Picrate Solution sufficient for a 96 well plate, mix together 2
ml sodium borate, 6 ml surfactant, 10 ml color reagent and 3.6 ml NaOH. This resultant
solution is stable for one week stored in the dark at room temperature.
Urine specimens were diluted 1:20 with Barnstead Nanopure water prior to use.
The creatinine standards were prepared as described in Table 3:
Table 3. Concentration of Creatinine Standards
Tube

Creatinine Standard
(μl)

Nanopure Water
(μl)

Final Concentration
(mg/dl creatinine)

A

0

500

0

B

50

450

2

C

100

400

4

D

150

350

6

E

200

300

8

F

250

250

10

G

300

200

12

H

375

125

15
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All reagents must reach room temperature before use. Calibrators, controls and
specimen samples should be assayed in duplicate. Once the procedure has been started,
all steps should be completed without interruption.
15 μl of each standard, diluted control urine and diluted cocaine positive urine
were pipetted into correspondingly labeled wells in duplicate. Next, 150 μl of the
alkaline picrate solution was pipetted into each well to initiate the reaction. The plate
was incubated on a plate shaker (approximately 200 rpm) for 10 minutes at room
temperature. The plate was read at 500 nm to calculate the initial absorbance. 5 μl of acid
solution was added to all wells and the plate was incubated for 20 minutes on a plate
shaker at room temperature. The final absorbance was calculated by reading the plate at
500 nm. A standard curve was produced and the concentration of creatinine in each of the
specimens was determined from the adjusted absorbance.

3.3 ELISA

Immunoassays are biochemical tests that measure the level of a substance in a
biological liquid, in our case urine. The assay utilizes the specific binding relationship of
antibody and antigen. Monoclonal antibodies are often used because they typically bind a
single site of a particular molecule; this property enhances specificity and accuracy.
Polyclonal antibodies have also been successfully applied for various immunoassays.
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Assay success depends on antibody affinity for the antigen. It is possible to measure both
the presence of antigen and antibodies.
Enzyme-linked Immunosorbent Assay (ELISA) uses antibodies (or antigens)
coupled with an enzyme to produce an antibody specific assay with the sensitivity of
simple enzyme assays. This allows an ELISA to provide a useful measurement of antigen
or antibody concentration. ELISA plates consist of 96 or 480 polyvinyl chloride
microwells containing enzymes, antigens or antibodies immobilized on a solid phase and
the substance. Depending on the type of ELISA, an antibody capable of detecting an
antigen or an antigen that will elicit the response of a particular antibody is allowed to
bind to the immobilized protein.
There are 5 types of ELISA: direct, indirect, sandwich, competitive and multiplex:
1. Direct ELISA: This method directly labels the antibody. The target antigen is
applied to the microwells of an ELISA plate; bound antigen may be quantitated
using colorimetric, chemiluminescent or fluorescent measurement. This method
provides relatively quick results with limited cross reactivity. There is little
opportunity for signal amplification with this method.
2. Indirect ELISA: This two step method uses a second antibody for detection.
The primary antibody is incubated with the antigen; the specimens in the wells
then incubate with a second labeled antibody capable of recognizing the primary
antibody. This method allows for considerable signal amplification.
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3. Sandwich ELISA: This method measures the amount of antigen ‟sandwiched‟
between two layers of antibodies. The sandwich ELISA requires the antigens to
be measured contain two or more antigenic sites capable of binding the capture
and detection antibodies; therefore, these assays are restricted to the quantitation
of multivalent antigens such as proteins or polysaccharides. Sandwich ELISAs are
excellent for quantitating antigens when the concentration of antigens is low or
the concentration of contaminating protein is high.
Briefly, the capture antibody is purified and bound to a solid phase (usually
attached to the bottom of a plate well). Specimens thought to contain the antigen
of interest are added to the microwells and allowed to complex with the capture
antibody. The plates are washed to remove unbound products and the labeled
detection antibody is allowed to bind to the antigen. This completes the
“sandwich”. The assay is quantitated using a colorimetric substrate to measure the
amount of detection antibody bound to the matrix.
4. Competitive ELISA: This method requires one reagent be conjugated to a
detection enzyme (horseradish peroxidase is one of the most commonly used).
This detection enzyme may be linked to the antigen or the primary antibody. The
microwells of the assay plate are coated with a purified unlabeled primary
antibody. Following this, the plate is incubated with unlabeled standards and
unknowns. The reaction is allowed to proceed to equilibrium; labeled conjugate
antigen is then added to the microwells. The conjugate will bind to the available
binding sites on the primary antibody. The plate is then developed with substrate
and color change is measured. In a competitive ELISA, there is an inverse
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relationship between the signal obtained and the concentration of the analyte in
the sample i.e. the more unlabeled antigens in the sample or standard, the lower
the amount of conjugated antigen bound.
5. Multiplex ELISA: This assay allows simultaneous detection of multiple
analytes arrayed in a single well. Detection method can be direct or indirect,
sandwich or competitive, labeling or non-labeling, depending upon antibody array
technologies.

There are further assay variations depending upon the labeling and signal
detection methodology. The basic approach stays the same: fixation of either antigen or
antibody and detection of the antibody-antigen complex. The general steps in
direct/competitive ELISAs can be seen in Figure 8.

Step 1: The antibody is attached to the walls of the microtiter plate.
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Step 2: Urine is added to the well to test for the presence of the antigen

Step 3: If the antigen is present in the urine, it will bind to the antibodies attached to the
microtiter walls.

Step 4: The plates are rinsed to remove test fluid and unbound antigen.

Step 5: A solution of modified antibodies is added. These antibodies carry a reporter
enzyme designed to elicit a color change when the antigen-antibody complex forms.
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Step 6: The sample is rinsed again to remove unbound antibodies. If the antigen is
present, a complex consisting of antigen, plate-bound antibody and enzyme-conjugated
antibody forms.

Step 7: The substrate of the enzyme is added. A color change indicates the presence of
the enzyme-labeled antibody and the antigen.
Figure 8. Common Steps in Direct/Competitive ELISA Assay
ELISAs were performed using a TECAN M200 Infinite Microplate Reader
(TECAN US Inc., Durham NC 27703). The TECAN M200 (Figure 9) is an automated
microplate reader is capable of UV & VIS Absorbance (ABS), Fluorescence (FL)
Intensity Top with Time-Resolved Fluorescence, Fluorescence Resonance Energy
Transfer, Fluorescence Intensity Bottom, Spectrally-Enhanced PMT, Photon-counting
Luminescence, Temperature Incubation and Cuvette Port Module, Single and Dual
Injectors. The M200 can measure wavelength range of in tunable 1nm increments,
Injector Module for fast kinetics in FL, Abs or Luminescent modes with one or two
injector(s). Available features include heated incubation to 420C, linear and orbital
shaking. The M200 accommodates 6, 12, 24, 48, 96 and 384-well microplate formats. It
is packaged with i-Control and Magellan software for instrument measurement control,
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spectral scanning, plate definition creation and raw data acquisition saved in a MS-Excel
format.

Figure 9. TECAN M200 Infinite Microplate Reader

A monochromator is an optical instrument that enables any wavelength to be
selected from a defined optical spectrum. It operates like a tunable optical filter, allowing
both the wavelength and bandwidth to be adjusted. A monochromator consists of an
entrance slit, a dispersive element and an exit slit. The dispersive element diffracts the
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light into the optical spectrum and projects it onto the exit slit. The dispersive element
may be a glass prism or an optical grating. The infinite® M200 is designed with optical
gratings. Rotation of the optical grating moves the spectrum across the exit slit so that
only a small part of the spectrum (band pass) passes through the exit slit. This means that
when the monochromator entrance slit is illuminated with white light, only light with a
specific wavelength (monochromatic light) passes through the exit slit. The wavelength
of this light is set by the rotation angle of the optical grating and the bandwidth is set by
the width of the exit slit. The bandwidth can be defined as full width at half maximum
(FWHM).
Monochromators block undesired wavelengths. This means when the
monochromator is set for light with a wavelength of 500 nm and the detector detects a
signal of 10,000 counts, light with different wavelengths is effectively dampened. Double
monochromators setups permit a higher level of blocking; two monochromators are
connected in series so that the exit slit of the first monochromator acts as the entrance slit
of the second monochromator. This arrangement boosts the blocking count by a factor of
103. In the infinite M200, a double monochromator is installed on both the excitation and
detection side. This opens the opportunity for easy selection of excitation and
fluorescence wavelengths with no limitations by cut off filters.
The i-control and Magellan software packaged with the TECAN M200 make
operation of the microplate reader relatively simple (Figure 10). The user is able to select
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Figure 10. I-Control/Magellan User Interface
from a variety of common microplate conformations. The injectors can be programmed
to automate reagent injection at specific stages of the assay, reducing operator error such
as faulty pipetting. The operator can set the absorbance wavelengths, measured and
reference, and determine the read pattern in the same panel. The Magellan software is a
wizard based interface; users can start a measurement wizard, evaluate results wizard,
create and edit sample ID lists wizard, and create and edit methods (analysis protocols)
wizard. Users can edit plate geometry to design the assay that suits their research. Results
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can be displayed as absorbance or concentration (calculated from the standard
curve/calibrator data) in each microwell (Figure 11). Results can also be displayed as
averages when specimens are assayed in duplicate.

Figure 11. Typical Magellan Microwell Absorbance Results
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Figure 12. TECAN Columbus Strip Washer
Use of an automated plate washer enhances assay accuracy by ensuring complete
well aspiration and washing. The laboratory used the Columbus Strip Washer (Figure
12). It is a fully automated microplate strip washer for 96- and 384-well plates. Its
features include manifolds of 8, 12 or 16 channels, crosswise aspiration, overflow and
bottom washing. Assay protocols can either be programmed on board or via PC interface
using the WinWash software. Thirty distinct methods can be programmed and stored
simplified operation. A liquid sensor system monitors the liquid level of waste, wash
buffer and rinse solution. Rinsing is fully automated, ensuring easy maintenance and
operation.
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3.3.1 Cocaine/Benzoylecgonine
3.3.1.1 General Principle of Assay
The principle of the Cocaine/Benzoylecgonine ELISA Kit used
(Cocaine/Benzoylecgonine Direct ELISA Kit #212-0480, Immunalysis Corporation,
Pomona, California 91767) is based upon the competitive binding to antibody of enzyme
labeled antigen and unlabeled antigen, in proportion to their concentration in the reaction
mixture. Unmetabolized cocaine urine concentration is far lower than that of its major
metabolite BE. Cocaine is undetectable (at a 50 ng/ml cut-off) 12 hours after
administration in comparison with BE which persists for up to 48 hours after use. ). It has
been suggested that a BE/cocaine ratio of less than 100 is indicative of use within the past
10 hours. Results are expressed in BE equivalents per ml.
A 20 μl aliquot of a diluted standard, control urine or cocaine positive (as
previously determined by EMIT) urine specimen is incubated with a 100 μl dilution of
horseradish peroxidase labeled BE derivative in micro-plate wells, coated with fixed
amounts of oriented high affinity purified polyclonal antibody. The wells are washed 6
times thoroughly and a chromogenic substrate added. The color produced is stopped
using a dilute acid stop solution and the wells read at 450 nm. The intensity of the color
developed is inversely proportional to the concentration of drug in the sample. The
technique is sensitive to 1 ng/ml.
The precision of the Immunalysis Cocaine/Benzoylecgonine Direct ELISA Kit
has been verified by assessment of the mean, standard deviation (SD) and coefficients of
variation (CV) in data resulting from repetitive assays. Assay sensitivity based on the
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minimum BE concentration required to produce a four standard deviation from assay Ao
is 1 ng/ml.

3.3.1.2 Assay Procedural Details
Kit contents:
1. 96 well micro-plate coated with polyclonal anti-benzoylecgonine and
polyclonal anti-cocaine
2. Cocaine/Benzoylecgonine-Enzyme Conjugate solution
3. Positive Reference Standard containing 50 ng/ml of BE dissolved in a synthetic
urine
4. Negative Standard
5. TMB chromogenic substrate
6. Stop Reagent containing 1 N hydrochloric acid

All reagents were brought to room temperature prior to use. Positive reference
standards of 0, 10, 25 and 50 ng/ml were prepared. Dilution of the urine specimens with
PBS pH 7.0 was unnecessary. 20 μl of appropriately diluted calibrators and standards
were pipetted to each well in duplicate. 20 μl of the diluted specimens were pipetted in
duplicate to the appropriate wells. Next, 100 μl of the Enzyme Conjugate was added to
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each well. After tapping the sides of the plate holder to ensure proper mixing, the plate
was incubated in the dark for 60 minutes at room temperature.
The microplate wells were washed 6 times with 350 μl Barnstead Nanopure
water. Following incubation, the microplate was inverted and slapped vigorously on
absorbent paper to ensure all residual moisture was removed. This step was critical to
remove residual enzyme conjugate. Next, 100 μl of Substrate reagent was added to each
well and the sides of plate holder tapped to ensure proper mixing. The plate was
incubated in the dark for 30 minutes at room temperature. 100 μl of Stop Solution was
added to each well, changing the blue color to yellow. Absorbance was measured at a
dual wavelength of 450 nm and 650 nm. A standard curve was produced and the
concentration of BE in each of the specimens was determined.

3.3.1.3 Cross-Reactivity
Aliquots of a human urine matrix were spiked with the following compounds at a
concentration of 5000 ng/ml. None of these compounds gave values in the assay that
were equal to or greater than the assay sensitivity level (<1 ng/ml).
Acetaminophen, Acetylsalicylic acid, Amphetamine, Aminopyrine, Ampicillin,
Amobarbital, Ascorbic acid, Atropine, Barbital, Butabarbital, Caffeine, Carbamazepine,
Codeine, Chloroquine, Chloropromazine, Carbromal ,Desipramine, Dextromethorphan,
Dextropropoxyphene, 5,5- Diphenylhydantoin, 10-11-Dihydrocarbamazepine, Diazepam,
Ethosuximide, Estriol, Estrone, Estradiol, Ethotoin, Glutethimide, Hexobarbital,
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Ibuprofen, Imipramine, Lidocaine, LSD, MDA, MDMA, Methadone, Methadone primary metabolite, Methaqualone, Methamphetamine, Metharbital, Mephenytoin, αMethyl-propylsuccinimide, Mephobarbital, Methyl PEMA, Methsuximide , 4Methylprimidone, Morphine, Meperidine, Niacinamide, Norethindrone, NNormethsuximide, Phenobarbital, Phensuximide, PEMA, Primidone, Phencyclidine,
Pentobarbital, Phenothiazine, Phenylpropanolamine, Procaine, Quinine, Secobarbital,
Tetracycline, Tetrahydrozoline, THCCOOH

3.3.2 Aldosterone
3.3.2.1 General Principle of Assay
The Aldosterone EIA kit used (Aldosterone Direct EIA Kit #11-ALDHU-E01,
ALPCO Diagnostics, Salem, NH 03079) follows the typical competitive binding
scenario. Unlabeled antigen (present in standards, control and samples) and an enzymelabeled antigen (conjugate) compete for a limited number of antibody binding sites on the
microplate. The kit can be used with urine specimens with significant pretreatment
(hydrolysis, neutralization and dilution). Approximately 1 ml of urine is required per
duplicate determination.
A 50 μl aliquot of a diluted standard, control urine or cocaine positive (as
previously determined by EMIT) urine specimen is incubated with a 100 μl dilution of
horseradish peroxidase labeled aldosterone derivative in micro-plate wells, coated with
fixed amounts of oriented high affinity purified polyclonal antibody. The wells are
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washed 3 times thoroughly and a chromogenic substrate added. The color produced is
stopped using a dilute acid stop solution and the wells read at 450 nm. The intensity of
the color formed is inversely proportional to the concentration of aldosterone in the
sample. A set of standards is used to plot a standard curve from which the amount of
aldosterone in samples and controls can be directly read.
The lower detection limit is calculated from the standard curve by determining the
resulting concentration of the mean OD of Calibrator A (based on 10 replicate analyses)
minus 2 SD. Therefore, the sensitivity of the Direct Aldosterone ELISA kit is 15pg/ml.
3.3.2.2 Assay Procedural Details
Kit Contents:
1. Rabbit Anti-Aldosterone Antibody Coated Microwell Plate
2. Aldosterone-Biotin: Avidin-Horse Radish Peroxidase (HRP) Conjugate
3. Aldosterone Calibrators
4. Control - Ready To Use.
5. Wash Buffer Concentrate
6. Assay Buffer
7. TMB Substrate
8. Stopping Solution
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3.3.2.3 Urine Pretreatment
1 ml of each urine sample was pipetted into an appropriately labeled glass or
polypropylene tube. 0.1 ml of 3.2 N HCl was added to every tube. 3.2 N HCl can be
made by adding 1 ml of concentrated HCl (12N) to 2.75 ml distilled water. Tubes were
then capped securely and heat for 1 hour at 60oC in the dark. Urine specimens were
neutralized by adding 0.1 ml of 3.2 N NaOH to every tube. 3.2 N NaOH can be made by
dissolving 1.28 grams of NaOH pellets into 10 ml distilled water. Tubes were then mixed
gently and thoroughly. The final step in pretreatment requires the dilution of samples
1:50 with calibrator A.
All reagents must reach room temperature before use. Positive reference
standards of 0, 20, 80, 300, 800 and 2000 pg/ml are provided ready to use. Calibrators,
controls and specimen samples should be assayed in duplicate. Once the procedure has
been started, all steps should be completed without interruption. The conjugate was
prepared by diluting the aldosterone-biotin: avidin-HRP concentrate 1:50 in assay buffer
(240 μl of HRP in 12ml of assay buffer). The wash buffer was prepared by diluting the
wash buffer concentrate 1:10 with Barnstead Nanopure water (50 ml of the wash buffer
concentrate in 450 ml of water).
50 μl of each calibrator, treated control urine and treated cocaine positive urine
were pipetted into correspondingly labeled wells in duplicate. Next, 100 μl of the
conjugate working solution was pipetted into each well. The plate was incubated on a
plate shaker (approximately 200 rpm) for 1 hour at room temperature. The wells were
washed 3 times with 300 μl of diluted wash buffer per well. The plate was tapped firmly
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against absorbent paper to ensure complete drying. 150 μl of TMB substrate was pipetted
into each well at timed intervals and the plate was incubated on a plate shaker for 10-15
minutes at room temperature. An alternate endpoint is to allow calibrator A to attain a
dark blue color for desired OD. 50 μl of stopping solution was added to each well at the
same timed intervals as in the TMB step. Finally, the plate was read at 450nm within 20
minutes after addition of the stopping solution. A standard curve was produced and the
concentration of aldosterone in each of the specimens was determined.
3.3.2.4 Cross-Reactivity
The following compounds cross-reacted at less than 0.001%: Androsterone,
Cortisone, 11-Deoxycortisol, 21-Deoxycortisol, Dihydrotestosterone, Estradiol, Estriol,
Estrone and Testosterone.

3.3.3 C Reactive Protein
3.3.3.1 General Principle of the Assay
The high sensitivity C Reactive Protein EIA kit used (high sensitivity C Reactive
Protein #30-9710s, ALPCO Diagnostics, Salem, NH 03079) was a sandwich enzyme
immunoassay intended for the quantitative determination of C reactive protein in plasma,
serum, stool and urine. The combination of two specific antibodies in the CRP ELISA
significantly reduces the possibility of false negatives. It is for in vitro diagnostic use
only. The wells of the microplate are coated with polyclonal antibodies directed against C
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reactive protein. The kit may be used with plasma, serum, stool and urine with little
pretreatment.
A 100 μl aliquot of a diluted standard, control urine or cocaine positive (as
previously determined by EMIT) urine specimen is added to the appropriate wells in
duplicate and incubated for an hour. The plate is then washed 5 times to remove all
unbound substances. 100 μl of the diluted peroxidase-labeled CRP conjugate antibody is
added and the plate is incubated for another hour. The plate is washed 5 times and a
chromogenic substrate is added. After allowing the plate to incubate for 20 minutes, an
acidic stopping solution is then added. The intensity of the color that forms is directly
proportional to the concentration of CRP in the sample. A dose response curve of the
absorbance (at 450 nm) unit vs. concentration is generated. CRP, present in the patient
samples, is determined directly from this calibration curve. The assay is sensitive to 0.124
ng/ml.

3.3.3.2 Assay Procedural Details
Kit Contents:
1. Microplate with precoated strips
2. Wash buffer concentrate
3. Antibody, (rabbit-anti-CRP, Peroxidase-labeled)
4. Calibrators, ready to use, (0; 1.9; 5.6; 16.7; 50; 150 ng/ml)
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5. Control
6. Sample buffer
7. TMB chromogenic substrate
8.

Stop solution containing sulfuric acid

All reagents and samples should be at room temperature (18-26 °C) prior to use.
Positive reference standards of 0, 1.9, 5.6, 16.7, 50 and 150 ng/ml are provided ready to
use. Urine specimens must be diluted 1:5 with sample dilution buffer. The wash buffer
concentrate was diluted 1:10 with Barnstead Nanopure Water before use (100 ml
concentrated wash buffer + 900 ml Nanopure Water). Crystals formed in the wash buffer
concentrate (a common occurrence due to high salt concentration in the stock solutions);
this necessitated soaking the concentrate in a 37°C using a water bath before dilution.
The conjugate required a 1: 100 dilution in wash buffer (100 μl concentrated conjugate +
9900 μl wash buffer).
Calibrators, controls and specimen samples should be assayed in duplicate. The
plate was washed 5 times prior to use by dispensing 250 μl of diluted wash buffer into
each well. 100 μl of appropriately diluted calibrators, standards and specimens were
pipetted to each well in duplicate. After incubating at room temperature on a plate shaker
for an hour, the contents of the wells were discarded and the plate was washed 5 times
with 250 μl diluted wash buffer. Next, 100 μl of the Enzyme Conjugate was added to
each well. After tapping the sides of the plate holder to ensure proper mixing, the plate
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was covered tightly and incubated on a plate shaker for 60 minutes at room temperature.
The microplate wells were washed 5 times with 250 μl diluted wash buffer. Next, 100 μl
of Substrate reagent was added to each well and the sides of plate holder tapped to ensure
proper mixing. The plate was incubated in the dark for 15 minutes at room temperature.
50 μl of Stop Solution was added to each well and the absorption was read immediately
at 450 nm against 620 nm as a reference.

3.3.3.3 Cross Reactivity
Alpha-1-Antitrypsin 0 %
Lysozyme 0 %
Albumin 0 %
Other acute phase proteins 0 %
No cross reactivity with CRP in mouse serum was observed.

3.3.4 Myeloperoxidase
3.3.4.1 General Principle of the Assay
The Myeloperoxidase EIA kit used (Myeloperoxidase #30-6630, ALPCO
Diagnostics, Salem, NH 03079)is a sandwich enzyme immunoassay intended for the
quantitative determination of MPO in plasma, serum, stool and urine. The combination of
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two specific antibodies in the MPO ELISA significantly reduces the possibility of false
negatives. It is for in vitro diagnostic use only. The wells of the microplate are coated
with polyclonal antibodies directed against MPO. The kit may be used with urine with
little pretreatment aside from dilution.
This ELISA is suitable for the quantitative determination of MPO in urine and
stool. In the first incubation step, the MPO in the samples is bound to available antibodies
against MPO immobilized on the surface of the microwells. To remove all unbound
substances, a washing step is carried out. In a second incubation step, a peroxidaselabeled antibody against MPO is added. After another washing step to remove all
unbound substances, the solid phase is incubated with the chromogenic substrate TMB.
An acidic stop solution is then added to stop the reaction. The intensity of the yellow
color is directly proportional to the concentration of MPO in the sample. A dose response
curve of the absorbance unit vs. concentration is generated, using results obtained from
the calibrators. MPO, present in the samples, is determined directly from this curve.
3.3.4.2 Assay Procedural Details
Kit Contents:
1. Microplate with precoated strips
2. Wash buffer concentrate
3. Detection Antibody (biotinylated)
4. Standards, lyophilized
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5. Control, lyophilized
6. Conjugate, (streptavidin peroxidase labeled)
7. Sample Dilution buffer
8. TMB chromogenic substrate
9.

Stop solution containing sulfuric acid

All reagents and samples should be at room temperature (18-26 °C) prior to use.
The Control and Positive reference standards of 0, 3.6, 11, 33 and 100 ng/ml are
lyophilized and must be reconstituted in 500 μl Barnstead Nanopure Water prior to use.
Urine specimens must be diluted 1:10 with sample dilution buffer. The wash buffer
concentrate was diluted 1:10 with Barnstead Nanopure Water before use (100 ml
concentrated wash buffer + 900 ml Nanopure Water). Crystals formed in the wash buffer
concentrate (a common occurrence due to high salt concentration in the stock solutions);
this necessitated soaking the concentrate in a 37°C using a water bath before dilution.
The conjugate required a 1: 101 dilution in wash buffer (100 μl concentrated conjugate +
10 ml wash buffer). The Antibody required a 1: 101 dilution in wash buffer (100 μl
concentrated antibody + 10 ml wash buffer).
Calibrators, controls and specimen samples should be assayed in duplicate. The
plate was washed 5 times prior to use by dispensing 250 μl of diluted wash buffer into
each well. 100 μl of appropriately diluted calibrators, standards and specimens were
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pipetted to each well in duplicate. After incubating at room temperature on a plate shaker
for an hour, the contents of the wells were discarded and the plate was washed 5 times
with 250 μl diluted wash buffer. Next, 100 μl of the diluted antibody was added to each
well. After tapping the sides of the plate holder to ensure proper mixing, the plate was
covered tightly and incubated on a plate shaker for 60 minutes at room temperature. The
microplate wells were washed 5 times with 250 μl diluted wash buffer. Next, 100 μl of
the diluted conjugate was added to each well. . After tapping the sides of the plate holder
to ensure proper mixing, the plate was covered tightly and incubated on a plate shaker for
60 minutes at room temperature. The microplate wells were washed 5 times with 250 μl
diluted wash buffer. Next, 100 μl of Substrate reagent was added to each well and the
sides of plate holder tapped to ensure proper mixing. The plate was incubated in the dark
for 15 minutes at room temperature. 50 μl of Stop Solution was added to each well and
the absorption was read immediately at 450 nm against 620 nm as a reference.

3.3.4.3 Cross Reactivity
No cross reactivity to other plasma proteins in stool.
Alpha-1-Antitrypsin, Albumin, CRP, Lysozyme, sIgA, PMN-Elastase, Calprotectin
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3.3.5 Microalbumin
3.3.5.1 General Principle of the Assay
The Microalbumin EIA kit used (Microalbumin # 24-MABHU-E01, ALPCO
Diagnostics, Salem, NH 03079)is a competitive enzyme immunoassay intended for the
quantitative determination of MAB in urine. The microwells of the assay plate are coated
with a purified unlabeled primary antibody. Following this, the plate is incubated with
unlabeled standards and unknowns. The reaction is allowed to proceed to equilibrium;
labeled conjugate antigen is then added to the microwells. The conjugate will bind to the
available binding sites on the primary antibody. The plate is then developed with
substrate and color change is measured.
After incubation for a fixed time, separation of bound albumin from free albumin
is achieved by simple decantation and plate washing. The enzyme activity on the plate is
measured using enzyme substrate and a chromogen. The absorbency of the color
developed is read in an EIA colorimetric reader. In a competitive ELISA, there is an
inverse relationship between the signal obtained and the concentration of the analyte in
the sample i.e. the more unlabeled antigens in the sample or standard, the lower the
amount of conjugated antigen bound. The concentration of albumin in the urine is
determined from a calibration curve.
The assay literature indicates that sensitivity was calculated by processing ten
zero calibrator (maximum binding) wells along with a calibration curve. Mean and
standard deviation were calculated for the absorbance of the ten zero calibrator wells.
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Apparent sensitivity was found to be 0.24 mg/ml. The antiserum is highly specific for
human albumin.
3.3.5.2 Assay Procedural Details
Kit Contents:
1. Microplate with precoated strips
2. Albumin Calibrators (5)
3. Albumin Enzyme Conjugate
4. Controls (2)
5. TMB chromogenic substrate
6.

Stop solution containing sulfuric acid

All reagents and samples should be at room temperature (18-26 °C) prior to use.
The Control and Positive reference standards packaged ready to use. Urine specimens
may be used without pretreatment or dilution. Calibrators, controls and specimen samples
should be assayed in duplicate. 10 μl of appropriately diluted calibrators, standards and
specimens were pipetted to each well in duplicate. Next 50 μl diluted enzyme conjugate
was added to every well. After incubating at room temperature on a plate shaker for an
hour, the contents of the wells were discarded and the plate was washed 5 times with 250
μl diluted wash buffer. Next, 100 μl of the diluted antibody was added to each well. After
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tapping the sides of the plate holder to ensure proper mixing, the plate was covered
tightly and incubated on a plate shaker for 60 minutes at room temperature. The
microplate wells were washed 5 times with 250 μl diluted wash buffer. Next, 100 μl of
the diluted conjugate was added to each well. After tapping the sides of the plate holder
to ensure proper mixing, the plate was covered tightly and incubated on a plate shaker for
60 minutes at room temperature. The microplate wells were washed 5 times with 250 μl
diluted wash buffer. Next, 100 μl of Substrate reagent was added to each well and the
sides of plate holder tapped to ensure proper mixing. The plate was incubated in the dark
for 15 minutes at room temperature. 50 μl of Stop Solution was added to each well and
the absorption was read immediately at 450 nm against 620 nm as a reference.

3.3.5.3 Cross Reactivity
No cross reactivity to bovine serum albumin, myoglobin, hemoglobin, and alpha
fetoprotein were noted at significantly high concentration.

3.3.6 Myoglobin
3.3.6.1 General Principle of the Assay
The Myoglobin EIA kit used (Myoglobin # 2110 Life Diagnostics, Inc., P.O. Box
5205, West Chester, PA, 19380) was a sandwich enzyme immunoassay intended for the
quantitative determination of myoglobin in serum and plasma. The combination of two
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specific antibodies in the myoglobin ELISA significantly reduces the possibility of false
negatives. It is for in vitro diagnostic use only. The wells of the microplate are coated
with polyclonal antibodies directed against myoglobin.
This ELISA is suitable for the quantitative determination of myoglobin in serum
and plasma. Although not labeled for use with urine specimens, the technical support
staff at Life Diagnostics (www.lifediagnostics.com 610-431-7707) asserted the assay was
fully compatible with urine specimens. 20 μl aliquots of standards, control urine or
cocaine positive urine specimens (as previously determined by EMIT) are incubated
simultaneously with two antibodies, resulting in myoglobin molecules being
„sandwiched‟ between the solid phase and enzyme-linked antibodies. To remove all
unbound substances, the plate is washed with Barnstead Nanopure Water. The
chromogenic substrate TMB is added and the plate is incubated for 20 minutes. An acidic
stop solution is then added to stop the reaction. The intensity of the yellow color is
directly proportional to the concentration of myoglobin in the sample. A dose response
curve of the absorbance unit vs. concentration is generated, using results obtained from
the calibrators. Myoglobin, present in the samples, is determined directly from this curve.
The lowest detectable level of myoglobin by this assay is estimated to be 5 ng/ml.
3.3.6.2 Assay Procedural Details
Kit Contents:
1. Murine Monoclonal Anti-Myoglobin-coated microtiter wells, 96 wells
2. Myoglobin Reference Standards (0, 25, 100, 250, 500 and 1000 ng/ml)
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3. Sample Diluent
4. Enzyme Conjugate Reagent
5. TMB Reagent
6. Stop Solution (1N HCl)

All reagents and samples should be at room temperature (18-26 °C) prior to use.
The myoglobin reference standards of 0, 25, 100, 250, 500 and 1000ng/ml are provided
ready to use. Urine specimens do not require dilution. 20 μl of calibrators, standards and
specimens were pipetted along with 200 μl of Enzyme Conjugate Reagent to each well in
duplicate and thoroughly mixed for 30 seconds. After incubating at room temperature for
45 minutes, the contents of the wells were discarded and the plate was washed 5 times
with 250 μl Barnstead Nanopure Water. Next, 100 μl of TMB Substrate reagent was
added to each well and the sides of plate holder tapped for 5 seconds to ensure proper
mixing. The plate was incubated for 20 minutes at room temperature. 100 μl of Stop
Solution was added to each well and the plate was gently mixed for 30 seconds. It is
important to make sure the blue color is completely changed to yellow before reading the
absorption. Finally, the absorption was read immediately at 450 nm against 620 nm as a
reference.
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3.3.6.3 Cross Reactivity
No cross reactivity is noted in the assay kit literature.

3.3.7 Heat Shock Protein 90α
3.3.7.1 General Principle of Assay
The principle of Heat Shock Protein 90α ELISA Kit used (Heat Shock Protein
90α Direct ELISA Kit #EKS-895, Assay Designs, Ann Arbor, MI 48108) is a
quantitative sandwich immunoassay. A 100 μl aliquot of a diluted standard, control urine
or cocaine positive (as previously determined by EMIT) urine specimen is pipetted into
the wells and Hsp90α present in a sample is bound to the wells by the immobilized
antibody. The wells are washed and the Detection Antibody is added. After washing
away unbound Detection Antibody, HRP-conjugated streptavidin is pipetted to the wells.
The wells are washed again, a TMB Substrate Reagent is added to the wells and color
develops in proportion to the amount of Hsp90α bound. The Stop Solution changes the
color from blue to yellow, and the intensity of the color is measured at 450 nm.
3.3.7.2 Assay Procedural Details
Kit contents:
1. Anti-Hsp90α Microplate
2. 20X Wash Buffer Concentrate
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3. Recombinant human Hsp90α Standard
4. Sample Diluent
5. HRP Conjugate
6. HRP Conjugate Diluent
7. TMB Substrate
8. Stop Solution
All reagents were brought to room temperature prior to use. Dilute 100 ml of
Wash Buffer Concentrate into 1900 ml Barnstead Nanopure Water to yield 2000 ml of 1x
Wash Buffer. Add 27.5 μl of HRP Conjugate into a tube with 11.0 μl 1x HRP Conjugate
diluent to prepare diluted HRP Conjugate. Mix thoroughly. The standards are prepared by
adding 2 μl 1 μg/ml Hsp90α stock standard to 500 μl Sample Diluent and performing
serial dilutions according to Table 4.
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Table 4. Hsp90α Serial Dilutions
Tube Volume and Source
of Hsp90α (μl)

Sample Diluent
(μl)

Final Hsp90α
Concentration
(ng/ml )

A

2.0 from the Hsp90α
standard vial

500

4

B

250 from Tube A

250

2

C

250 from Tube B

250

1

D

250 from Tube C

250

0.5

E

250 from Tube D

250

0.25

F

250 from Tube E

250

0.125

G

250 from Tube F

250

0.0625

H

0

250

0

Urine specimens do not require dilution. 100 μl of calibrators, standards and
specimens were pipetted to each well in duplicate and thoroughly mixed for 30 seconds.
After incubating at room temperature for 60 minutes, the contents of the wells were
discarded and the plate was washed 6 times with 300 μl Wash Buffer. Next, 100 μl of
HRP Conjugate was added to each well except H1 and H2. After incubating at room
temperature for 60 minutes, the contents of the wells were discarded and the plate was
washed 6 times with 300 μl Wash Buffer.

Next, 100 μl of TMB Substrate reagent was

added to each well and the sides of plate holder tapped for 5 seconds to ensure proper
mixing. The plate was incubated for 20 minutes at room temperature. 100 μl of Stop
Solution was added to each well and the plate was gently mixed for 30 seconds. It is
important to make sure the blue color is completely changed to yellow before reading the
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absorption. Finally, the absorption was read immediately at 450 nm against 620 nm as a
reference.

3.3.7.3 Cross-Reactivity
Assay Designs‟ Hsp90α ELISA is specific for Hsp90α and will not react with
Hsp90β. The assay does not cross react with 100ng/mL of Grp94, Hsp60, Hsp70. The
Hsp90α ELISA has been certified for the detection of human Hsp90α.

3.3.8 Vascular Endothelial Growth Factor
3.3.8.1 General Principle of Assay
The principle of Vascular Endothelial Growth Factor ELISA Kit used (Vascular
Endothelial Growth Factor ELISA Kit #ELH-VEGF-001, RayBiotech Corporation,
Norcross, GA 30092) is intended for the quantitative measurement of human VEGF in
serum, plasma, cell culture supernatants and urine. The assay is based upon the
competitive binding to antibody of enzyme labeled antigen and unlabeled antigen, in
proportion to their concentration in the reaction mixture.
A 20 μl aliquot of a diluted standard, control urine or cocaine positive (as
previously determined by EMIT) urine specimen is pipetted into the wells and VEGF
present in a sample is bound to the wells by the immobilized antibody. The wells are
washed and the Detection Antibody is added. After washing away unbound Detection
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Antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are washed
again, a TMB Substrate Reagent is added to the wells and color develops in proportion to
the amount of VEGF bound. The Stop Solution changes the color from blue to yellow,
and the intensity of the color is measured at 450 nm.
3.3.8.2 Assay Procedural Details
Kit contents:
1. VEGF Microplate
2. Wash Buffer Concentrate
3. Recombinant human VEGF Standard
4. Assay Diluent A (serum/plasma)
5. Assay Diluent B (urine and other body fluids)
6. Detection Antibody VEGF ( biotinylated anti-humanVEGF)
7. HRP-Streptavidin concentrate
8. TMB One-Step Substrate Reagent
9. Stop Solution (2 M sulfuric acid)

All reagents were brought to room temperature prior to use. Assay Diluent B is
used for dilution of culture supernatants and urine; Assay Diluent B is prepared by
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diluting the contents of the vial 5-fold with Barnstead Nanopure Water. Dilute 20 ml of
Wash Buffer Concentrate into Barnstead Nanopure Water to yield 400 ml of 1x Wash
Buffer. Add 100 μl of 1x Assay Diluent B into the vial to prepare a detection antibody
concentrate. Add 2 μl of HRP-Streptavidin concentrate into a tube with 198.0 μl 1x
Assay Diluent B to prepare a 100-fold diluted HRP- Streptavidin. Mix thoroughly and
then pipette 100 μl of prepared 100-fold diluted solution into a tube with 15 ml 1x Assay
Diluent B to prepare a final 15,000 fold diluted HRP-Streptavidin solution. The standards
are prepared by adding 60 μl 50 ng/ml VEGF stock standard to 440 μl Assay Diluent B
and performing serial dilutions according to Table 5:

Table 5. VEGF Serial Dilutions
Tube Volume and Source
of VEGF (μl)

Assay Diluent B
(μl)

Final VEGF
Concentration
(pg/ml )

A

60 from the VEGF
standard vial

440

6000

B

200 from Tube A

400

2000

C

200 from Tube B

400

666.7

D

200 from Tube C

400

222.2

E

200 from Tube D

400

74.07

F

200 from Tube E

400

24.69

G

200 from Tube F

400

8.23

H

0

400

0
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100 μl of appropriately diluted calibrators and standards were pipetted to each
well in duplicate. 100 μl of the specimens were pipetted in duplicate to the appropriate
wells. The microplate was covered and incubated for 2.5 hours at room temperature or
over night at 4°C with gentle shaking. Wash the plate 4 times with 1x Wash Solution.
After the last wash, the plate was inverted and blotted against clean paper towels. Next,
100 μl of the diluted biotinylated antibody was added to each well. The plate was
incubated for 1 hour at room temperature with gentle shaking. The wash cycle was
repeated. 100 μl of prepared Streptavidin solution was added to each cell. After tapping
the sides of the plate holder to ensure proper mixing, the plate was incubated for 45
minutes at room temperature on a plate shaker. The wash cycle was repeated a final time.
100 μl of TMB Substrate Reagent was added to each well and the plate was incubated for
30 minutes at room temperature in the dark with on a plate shaker. The reaction was
stopped with the addition of 50 μl of Stop Solution to each well. The plate was read at
450 nm immediately. A standard curve was generated and the concentration of VEGF in
each of the specimens was determined.

3.3.8.3 Cross-Reactivity
This ELISA kit shows no cross-reactivity with any of the following cytokines:
human Angiogenin, BDNF, BLC, ENA-78, FGF-4, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5,
IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 p70, IL-12 p40, IL-13, IL-15, IL-309, IP-10, GCSF, GM-CSF, IFN-γ, Leptin, MCP-1, MCP-2, MCP-3, MDC, MIP-1α, MIP-1 β, MIP-
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1δ, PARC, PDGF, RANTES, SCF, TARC, TGF-β, TIMP-1, TIMP-2, TNF-α, TNF-β,
TPO

3.3.9 Human Matrix Metalloproteinase 9/Neutrophil Gelatinase Associated Lipocalin
3.3.9.1 General Principle of Assay
The principle of Human Matrix Metalloproteinase 9/Neutrophil Gelatinase
Associated Lipocalin ELISA Kit used (Human Matrix Metalloproteinase 9/Neutrophil
Gelatinase Associated Lipocalin Direct ELISA Kit #DM9L20, R&D Systems,
Minneapolis, Minnesota 55413) a sandwich enzyme immunoassay intended for the
quantitative determination of MMP-9/NGAL in cell culture supernates, serum, plasma,
urine and saliva. The combination of two specific antibodies in the MMP-9/NGAL
ELISA significantly reduces the possibility of false negatives. It is for research use only.
The wells of the microplate are coated with polyclonal antibodies directed against MMP9/NGAL.
A 50 μl aliquot of a standard, control urine or cocaine positive (as previously
determined by EMIT) urine specimen is incubated with 100 μl Assay Diluent for 3 hours
at room temperature. The wells are washed 3 times thoroughly and 200 μl of MMP9/NGAL conjugate is added. The plate is incubated and washed again before a
chromogenic substrate added. The color produced is stopped using a dilute acid stop
solution and the wells read at 450 nm. The intensity of the color developed is inversely
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proportional to the concentration of drug in the sample. The technique is sensitive to
0.013 ng/ml.
3.3.9.2 Assay Procedural Details
Kit contents:
1. 96 well micro-plate coated with mouse monoclonal anti-MMP-9/NGAL
2. MMP-9/NGAL Conjugate solution
3. Standard containing 20 ng/ml of MMP-9/NGAL , lyophilized
4. Assay Diluent RD1-87
5. Calibrator Diluent RD5-10
6. Color Reagent A
7. Color Reagent B
8. Wash Buffer Concentrate
9. Stop Reagent containing 2 N sulfuric acid

All reagents were brought to room temperature prior to use. The Wash Buffer
was prepared by diluting 20 ml of Wash Buffer Concentrate in 480 ml Barnstead
Nanopure Water. Color Reagents A and B were mixed together in equal volumes to
prepare the Substrate Solution. It has to be used within 15 minutes of preparation. The
lyophilized MMP-9/NGAL standard was reconstituted with 1 ml Barnstead Nanopure
Water to yield a 20 ng/ml MMP-9/NGAL stock solution. Calibrators were prepared from
the stock solution according to Table 6:
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Table 6. NGAL Serial Dilution Table
Tube

Volume and Source of
MMP-9/NGAL (μl)

Calibrator
Diluent RD5-10
(μl)

Final Concentration
(ng/ml MMP-9/NGAL)

A

200 from Stock Solution

200

10

B

200 from Tube A

200

5

C

200 from Tube B

200

2.5

D

200 from Tube C

200

1.25

E

200 from Tube D

200

0.625

F

200 from Tube E

200

0.312

G

0

200

0

100 μl of Assay Diluent RD1-87 was added to each well. 50 μl aliquots of the
standards, control urine or cocaine positive urine specimens were pipetted in duplicate to
the appropriate wells. After tapping the sides of the plate holder to ensure proper mixing,
the plate was incubated for 3 hours at room temperature. The microplate wells were
aspirated and washed 4 times with 400 μl Barnstead Nanopure water. Following
incubation, the microplate was inverted and slapped vigorously on absorbent paper to
ensure all residual moisture was removed. Next, 200 μl of the Conjugate was added to
each well and the plate was incubated for 1 hour at room temperature. The aspiration and
wash cycle was repeated. Next, 200 μl of Substrate reagent was added to each well and
the sides of plate holder tapped to ensure proper mixing. The plate was incubated in the
dark for 30 minutes at room temperature. Finally, 50 μl of Stop Solution was added to
each well, changing the blue color to yellow.
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Absorbance was measured at a wavelength of 450 nm. A standard curve was
produced and the concentration of MMP-9/NGAL in each of the specimens was
determined.
No significant cross-reactivity has been noted.

3.3.10 Pro-atrial natriuretic peptide (1-98)
3.3.10.1 General Principle of Assay
The pro-atrial natriuretic peptide (1-98) EIA kit used (proANP Direct EIA Kit #
04-BI-20892, ALPCO Diagnostics, Salem, NH 03079) follows the typical direct binding
scenario. It is appropriate for research use only. The wells of the microplate are coated
with polyclonal antibodies directed against proANP. The kit may be used with urine with
no pretreatment.
A 10 μl aliquot of a standard, control urine or cocaine positive (as previously
determined by EMIT) urine specimen is added to each well except the blank. 200 μl of
Conjugate is added to all the wells, except the blanks, and incubated in the dark for 3
hours at room temperature. The wells are washed 5 times thoroughly and 200 μl of
Substrate is added. The plate is incubated the reaction is stopped using a dilute acid stop
solution. Finally, measure the absorbance at 450 nm with a reference of 620 nm. The
intensity of the color developed is proportional to the concentration of drug in the sample.
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3.3.10.2 Assay Procedural Details
Kit Contents:
1. Polyclonal sheep anti proANP Coated Microwell Plate
2. Conjugate (polyclonal anti proANP antibody –HRPO)
3. ProANP standards, lyophilized
4. Control, lyophilized
5. Wash Buffer Concentrate
6. Assay Buffer
7. TMB Substrate
8. Stop Solution (Sulfuric Acid)
All reagents must reach room temperature before use. The Control and Positive
reference standards of 0, 0.63, 1.25, 2.5, 5.0 and 10.0 nmol/l are lyophilized and required
reconstitution with 250 μl Barnstead Nanopure water. Calibrators, controls and specimen
samples should be assayed in duplicate. Once the procedure has been started, all steps
should be completed without interruption. The conjugate (polyclonal anti proANP
antibody –HRPO) was provided ready to use. The wash buffer was prepared by diluting
the wash buffer concentrate 1:20 with Barnstead Nanopure water (50 ml of the wash
buffer concentrate in 950 ml of water).
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10 μl of each calibrator, treated control urine and treated cocaine positive urine
(as determined by EMIT) were pipetted into correspondingly labeled wells in duplicate.
Next, 200 μl of the conjugate working solution was pipetted into each well, except the
blanks. The plate was incubated for 3 hours at room temperature in the dark. The wells
were aspirated and washed 5 times with 300 μl of diluted wash buffer per well. The plate
was tapped firmly against absorbent paper to ensure complete drying. 200 μl of TMB
substrate was pipetted into each well and the plate was incubated on a plate shaker for 30
minutes at room temperature in the dark. 50 μl of stopping solution was added to each
well and the plate was read at 450nm with a reference of 620 nm. A standard curve was
produced and the concentration of proANP in each of the specimens was determined.
3.3.10.3 Cross-Reactivity
proANP (1-30) < 1%
proANP (31-67) <1%
proANP (79-98) <1%
alpha ANP (99-126) <1%
proBNP (8-29) <1%
proBNP (32-57) <1%
proCNP (1-19) <1%
proCNP (30-50) <1%
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proCNP (51-97) <1%
The assay also detects mouse and rat proANP (1-98).

3.3.11 Interleukin 1α
3.3.11.1 General Principle of the Assay
The Interleukin 1α EIA kit used (Interleukin 1α #583301, Cayman Chemicals,
Ann Arbor, MI 48108) is a sandwich enzyme immunoassay intended for the quantitative
determination of Interleukin 1α in serum and plasma. Cayman Chemical Technical
Support verified the assay was compatible with urine specimens so long as the standards
are diluted with an appropriate sample matrix blank (SMB). Synthetic Urine from
Immunalysis (Synthetic Urine with Creatinine Dry Powder #SUP-5, Immunalysis
Corporation, Pomona, CA 91767) was used for the sample matrix blank. The
combination of two specific antibodies in the Interleukin 1α ELISA significantly reduces
the possibility of false negatives. It is for research use only. The wells of the microplate
are coated with polyclonal antibodies directed against Interleukin 1α.
A 100 μl aliquot of a diluted standard, control urine or cocaine positive (as
previously determined by EMIT) urine specimen is added to the appropriate wells in
duplicate. Next, 100 μl of Acetylcholinesterase: Interleukin-1 α Fab‟ Conjugate is added
to all wells except the blanks and incubated for overnight at 4 °C. The plate is then
washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of Ellman‟s
Reagent is added to each well and the plate is incubated in the dark. The reaction is
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monitored for several hours until the S1 wells are visibly yellow. The intensity of the
color that forms is directly proportional to the concentration of Interleukin-1 α in the
sample. A dose response curve of the absorbance (at 405 nm) unit vs. concentration is
generated. Interleukin-1 α, present in the patient samples, is determined directly from this
calibration curve. The assay is sensitive to 1.5 pg/ml Interleukin-1 α.

3.3.11.2 Assay Procedural Details
Kit Contents:
1. Microplate with precoated strips
2. Interleukin-1 α standard
3. Non-specific Mouse Serum
4. Sample Matrix Blank for plasma, serum (cannot be used for this assay)
5. Acetylcholinesterase: Interleukin-1 α Fab‟ Conjugate
6. EIA Buffer Concentrate
7. Wash Buffer Concentrate
8.

Tween

9.

Ellman‟s Reagent
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All reagents and samples should be at room temperature (18-26 °C) prior to use.
The EIA Buffer concentrate was reconstituted with 90 ml of Barnstead Nanopure water.
The Wash Buffer was prepared by bringing 5 ml of wash buffer concentrate to a total
volume of 2 L with Barnstead Nanopure water and then adding 1 ml Tween. The
Acetylcholinesterase: Interleukin-1 α Fab‟ Conjugate was reconstituted with 10 ml of
EIA buffer. The urine specimens were used without any dilution. Interleukin-1 α
standards required reconstitution with 2 ml EIA Buffer prior to dilution with SMB. This
initial dilution yielded a stock solution of 5 ng/ml Interleukin-1 α. The Immunalysis
Synthetic Urine served as the SMB; the lyophilized urine was reconstituted with
Barnstead Nanopure water prior to use. 4.5 L of Nanopure water were added to the
contents of the pouch. The solution was stirred until the lyophilized urine dissolved
completely. The total volume was adjusted to 5 L with Nanopure water. The synthetic
urine is stable for 1 year when stored at 4°C.
The Interleukin-1 α standards were prepared as described in Table 7:
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Table 7. Concentration of Interleukin-1 α Standards
Tube

Volume and Source of
Interleukin-1 α (μl)

Sample Matrix
Buffer (μl)

Final Concentration
(pg/ml Interleukin-1α)

A

50 from Stock Solution

Dilute to 1 ml total

250

B

500 from Tube A

500

125

C

500 from Tube B

500

62.5

D

500 from Tube C

500

31.25

E

500 from Tube D

500

15.6

F

500 from Tube E

500

7.8

G

500 from Tube F

500

3.9

H

0

500

0

Calibrators, controls and specimen samples should be assayed in duplicate. 100
μl of appropriately diluted calibrators, standards and specimens were pipetted to each
well in duplicate. . Next, 100 μl of Acetylcholinesterase: Interleukin-1 α Fab‟ Conjugate
is added to all wells except the blanks and incubated for overnight at 4 °C. The plate is
then washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of
Ellman‟s Reagent is added to each well and the plate is incubated in the dark. The
reaction is monitored for several hours until the S1 wells are visibly yellow. The intensity
of the color that forms is directly proportional to the concentration of Interleukin-1 α in
the sample. The absorption was read immediately at 405 nm.
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3.3.12 Interleukin 1β
3.3.12.1 General Principle of the Assay
The Interleukin 1β EIA kit used (Interleukin 1β #583311, Cayman Chemicals,
Ann Arbor, MI 48108) is a sandwich enzyme immunoassay intended for the quantitative
determination of Interleukin 1β in serum and plasma. Cayman Chemical Technical
Support verified the assay was compatible with urine specimens so long as the standards
are diluted with an appropriate sample matrix blank (SMB). Synthetic Urine from
Immunalysis (Synthetic Urine with Creatinine Dry Powder #SUP-5, Immunalysis
Corporation, Pomona, CA 91767) was used for the sample matrix blank. The
combination of two specific antibodies in the Interleukin 1β ELISA significantly reduces
the possibility of false negatives. It is for research use only. The wells of the microplate
are coated with polyclonal antibodies directed against Interleukin 1β.
A 100 μl aliquot of a diluted standard, control urine or cocaine positive (as
previously determined by EMIT) urine specimen is added to the appropriate wells in
duplicate. Next, 100 μl of Acetylcholinesterase: Interleukin-1 β Fab‟ Conjugate is added
to all wells except the blanks and incubated for overnight at 4 °C. The plate is then
washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of Ellman‟s
Reagent is added to each well and the plate is incubated in the dark. The reaction is
monitored for several hours until the S1 (250 pg/ml) wells are visibly yellow. The
intensity of the color that forms is directly proportional to the concentration of
Interleukin-1 β in the sample. A dose response curve of the absorbance (at 405 nm) unit
vs. concentration is generated. Interleukin-1 β, present in the patient samples, is
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determined directly from this calibration curve. The assay is sensitive to 1.5 pg/ml
Interleukin-1 β.

3.3.12.2 Assay Procedural Details
Kit Contents:
1. Microplate with precoated strips
2. Interleukin-1 β standard
3. Non-specific Mouse Serum
4. Sample Matrix Blank for plasma, serum (cannot be used for this assay)
5. Acetylcholinesterase: Interleukin-1 β Fab‟ Conjugate
6. EIA Buffer Concentrate
7. Wash Buffer Concentrate
8.

Tween

9.

Ellman‟s Reagent

All reagents and samples should be at room temperature (18-26 °C) prior to use.
The EIA Buffer concentrate was reconstituted with 90 ml of Barnstead Nanopure water.
The Wash Buffer was prepared by bringing 5 ml of wash buffer concentrate to a total
volume of 2 L with Barnstead Nanopure water and then adding 1 ml Tween. The
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Acetylcholinesterase: Interleukin-1 β Fab‟ Conjugate was reconstituted with 10 ml of
EIA buffer. The urine specimens were used without any dilution. Interleukin-1 β
standards required reconstitution with 2 ml EIA Buffer prior to dilution with SMB. This
initial dilution yielded a stock solution of 5 ng/ml Interleukin-1 β. The Immunalysis
Synthetic Urine served as the SMB; the lyophilized urine was reconstituted with
Barnstead Nanopure water prior to use. 4.5 L of Nanopure water were added to the
contents of the pouch. The solution was stirred until the lyophilized urine dissolved
completely. The total volume was adjusted to 5 L with Nanopure water. The synthetic
urine is stable for 1 year when stored at 4°C.
The Interleukin-1 β standards were prepared as described in Table 8:
Table 8. Concentration of Interleukin-1 β Standards
Tube

Volume and Source
of Interleukin-1 β (μl)

Sample Matrix
Buffer (μl)

Final Concentration
(pg/ml Interleukin-1β)

A

50 from Stock Solution

Dilute to 1 ml total

250

B

500 from Tube A

500

125

C

500 from Tube B

500

62.5

D

500 from Tube C

500

31.25

E

500 from Tube D

500

15.6

F

500 from Tube E

500

7.8

G

500 from Tube F

500

3.9

H

0

500

0
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Calibrators, controls and specimen samples should be assayed in duplicate. 100
μl of appropriately diluted calibrators, standards and specimens were pipetted to each
well in duplicate. . Next, 100 μl of Acetylcholinesterase: Interleukin-1 β Fab‟ Conjugate
is added to all wells except the blanks and incubated for overnight at 4 °C. The plate is
then washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of
Ellman‟s Reagent is added to each well and the plate is incubated in the dark. The
reaction is monitored for several hours until the S1 wells are visibly yellow. The intensity
of the color that forms is directly proportional to the concentration of Interleukin-1 β in
the sample. The absorption was read immediately at 405 nm.

3.3.13 Interleukin 6
3.3.13.1 General Principle of the Assay
The Interleukin 6 EIA kit used (Interleukin 6 #583361, Cayman Chemicals, Ann
Arbor, MI 48108) is a sandwich enzyme immunoassay intended for the quantitative
determination of Interleukin 6 in serum and plasma. Cayman Chemical Technical
Support verified the assay was compatible with urine specimens so long as the standards
are diluted with an appropriate sample matrix blank (SMB). Synthetic Urine from
Immunalysis (Synthetic Urine with Creatinine Dry Powder #SUP-5, Immunalysis
Corporation, Pomona, CA 91767) was used for the sample matrix blank. The
combination of two specific antibodies in the Interleukin 6 ELISA significantly reduces
the possibility of false negatives. It is for research use only. The wells of the microplate
are coated with polyclonal antibodies directed against Interleukin 6.
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A 100 μl aliquot of a diluted standard, control urine or cocaine positive (as
previously determined by EMIT) urine specimen is added to the appropriate wells in
duplicate. Next, 100 μl of Acetylcholinesterase: Interleukin-6 Fab‟ Conjugate is added to
all wells except the blanks and incubated for overnight at 4 °C. The plate is then washed
5 times with Wash Buffer to remove all unbound substances. 200 μl of Ellman‟s Reagent
is added to each well and the plate is incubated in the dark. The reaction is monitored for
several hours until the S1 (250 pg/ml) wells are visibly yellow. The intensity of the color
that forms is directly proportional to the concentration of Interleukin-6 in the sample. A
dose response curve of the absorbance (at 405 nm) unit vs. concentration is generated.
Interleukin 6 present in the patient samples is determined directly from this calibration
curve. The assay is sensitive to 7.8 pg/ml Interleukin-6.

3.3.13.2 Assay Procedural Details
Kit Contents:
1. Microplate with precoated strips
2. Interleukin-6 standard
3. Non-specific Mouse Serum
4. Sample Matrix Blank for plasma, serum (cannot be used for this assay)
5. Acetylcholinesterase: Interleukin-6 Fab‟ Conjugate
6. EIA Buffer Concentrate
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7. Wash Buffer Concentrate
8.

Tween 20

9.

Ellman‟s Reagent

All reagents and samples should be at room temperature (18-26 °C) prior to use.
The EIA Buffer concentrate was reconstituted with 90 ml of Barnstead Nanopure water.
The Wash Buffer was prepared by bringing 5 ml of wash buffer concentrate to a total
volume of 2 L with Barnstead Nanopure water and then adding 1 ml Tween. The
Acetylcholinesterase: Interleukin-6 Fab‟ Conjugate was reconstituted with 10 ml of EIA
buffer. The urine specimens were used without any dilution. Interleukin-6 standards
required reconstitution with 2 ml EIA Buffer prior to dilution with SMB. This initial
dilution yielded a stock solution of 5 ng/ml Interleukin-6. The Immunalysis Synthetic
Urine served as the SMB; the lyophilized urine was reconstituted with Barnstead
Nanopure water prior to use. 4.5 L of Nanopure water were added to the contents of the
pouch. The solution was stirred until the lyophilized urine dissolved completely. The total
volume was adjusted to 5 L with Nanopure water. The synthetic urine is stable for 1 year
when stored at 4°C.
The Interleukin-6 standards were prepared as described in the table below (Table
9):
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Table 9. Concentration of Interleukin-6 Standards
Tube

Volume and Source of
Interleukin-6 (μl)

Sample Matrix
Buffer (μl)

Final Concentration
(pg/ml Interleukin-6)

A

50 from Stock Solution

Dilute to 1 ml total

250

B

500 from Tube A

500

125

C

500 from Tube B

500

62.5

D

500 from Tube C

500

31.3

E

500 from Tube D

500

15.6

F

500 from Tube E

500

7.8

G

500 from Tube F

500

3.9

H

0

500

0

Calibrators, controls and specimen samples should be assayed in duplicate. 100
μl of appropriately diluted calibrators, standards and specimens were pipetted to each
well in duplicate. . Next, 100 μl of Acetylcholinesterase: Interleukin-6 Fab‟ Conjugate is
added to all wells except the blanks and incubated for overnight at 4 °C. The plate is then
washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of Ellman‟s
Reagent is added to each well and the plate is incubated in the dark. The reaction is
monitored for several hours until the S1 (250 pg/ml standard) wells are visibly yellow.
The intensity of the color that forms is directly proportional to the concentration of
Interleukin-6 in the sample. The absorption was read immediately at 405 nm.
Crossreactivity with the other interleukins is limited.
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Chapter 4.0
Results

Results were analyzed using a Student‟s t test for significance (JMP Start
Statistics, Release 4.0.4 SAS Institute, 2001) was used to compare biomarker
concentration in the male and female, control and cocaine positive specimens. Because
the data was not parametric, the Wilcoxon Rank Sums and Mann Whitney U tests were
also used to test the means. In addition, the Tukey-Kramer HSD test was also used to
analyze the means. The results were the same regardless of the analysis performed.
4.1 Gender
4.1.1 Assay results in Male and Female Control Urines
A summary of the differences in marker expression between male and female
control urine specimens is presented in Table 10. The individual results are standardized
and expressed per milligram creatinine. The mean aldosterone concentration was
statistically significantly (p=0.0223) in female urine when compared to male urine
specimens. The same was true for IL1 α (p=.0007) and IL1 β (p=.0198). The results for
hsCRP (p=.0662) and MPO (p=.0562) are suggestive of statistical significance. There
was no statistically significant difference in the other biomarkers.
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Table 10. Comparison of Assay results in Male and Female Control Urines

Control
Assay
Male

Female

p

Total Protein (pg)

32.2 + 12.1

65.9+20.8

.2294

Aldosterone (pg)

1907.7 + 356.7

4917.96+1159.9

.0223*

hsCRP (ng)

0.78+ .6

202.3+103.0

.0662

Myeloperoxidase (ng)

20.5+ 7.9

187.1+81.3

.0562

Microalbumin (ug)

18.4+ 7.3

41.2+14.4

.1763

Hsp90 α (ng)

0.92+ .4

0.3+.2

.2133

VEGF (pg)

2453.0+ 972.5

3286.2+1402.6

.6205

proANP (nmol)

0.3+.1

0.34+.1

.5482

Myoglobin (ng)

15.5+9.8

26.5+9.1

.393

NGAL (ng)

0.08+.1

12.5+9.8

.2213

IL6 (pg)

0.86+.4

7.52+4.4

.1532

IL1 α (pg)

3.8+3.8

56.9+12.5

.0007*

IL1 β (pg)

2.2+1.0

6.6+1.4

.0198*

*significant at p<0.05
values expressed as mean + standard error of the mean (SEM)

4.1.2 Assay results in Male and Female Cocaine Positive Urines
A summary of the differences in marker expression between male and female
cocaine positive urine specimens is presented in Table 11. The individual results are
96

standardized and expressed per milligram creatinine. The results for Hsp90α (p=.0650)
are suggestive of statistical significance. There was no statistically significant difference
in the other biomarkers.
Table 11. Comparison of Assay results in Male and Female Cocaine Positive Urines

Cocaine Positive
Assay
Male

Female

p

Total Protein (pg)

66.9+22.4

47.4+3.2

.4612

Aldosterone (pg)

3331.8+399.8

3463.6+723.2

.8600

hsCRP (ng)

42.1+44.4

47.4+34.3

.9275

Myeloperoxidase (ng)

25.15+9.7

52.1+22.1

.2140

Microalbumin (ug)

32.9+9.7

40.5+10.2

.5995

Hsp90 α (ng)

0.9+.3

0.02+.1

.0650

VEGF (pg)

2900.9+1168

1308.4+351.9

.2535

proANP (nmol)

0.5+.1

0.3+.1

.3612

Myoglobin (ng)

36.9+4.8

45.9+9.8

.3586

NGAL (ng)

0.3+.12

20.2+12.0

.1534

IL6 (pg)

3.8+ 8.9

6.3+4.6

.6521

IL1 α (pg)

1.74+1.07

26.2+12.3

.0907

IL1 β (pg)

2.5+.5

9.5+3.4

.0846

* significant at p<0.05
values expressed as mean + standard error of the mean (SEM)
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4.2 Cocaine
4.2.1 Assay Results in Male Control and Cocaine Positive Urine Specimens
A summary of the differences in marker expression between control and cocaine
positive male urine specimens is presented in Table 12. The individual assay results are
standardized and expressed per milligram creatinine. The mean aldosterone concentration
was significantly higher (p=0.0095) in cocaine positive urine when compared to control
urine specimens. The mean myoglobin concentration was significantly higher
(p=0.0332) in cocaine positive urine when compared to control urine specimens. There
was no statistically significant difference in the other biomarkers.

4.2.2 Assay Results in Female Control and Cocaine Positive Urine Specimens
A summary of the differences in marker expression in control and cocaine
positive female urine specimens is presented in Table 13. The individual results are
standardized and expressed per milligram creatinine. There were no statistically
significant differences between the control and cocaine positive means for any of the
assays.
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Table 12. Comparison of Assay Results in Male Control and Cocaine Positive Urine

Male
Assay
Control

Cocaine Positive

p

Total Protein (pg)

32.2 + 12.1

66.9+22.4

0.2377

Aldosterone (pg)

1907.7 + 356.7

3331.8+399.8

0.0095*

hsCRP (ng)

0.78+ .6

42.1+44.4

0.3668

Myeloperoxidase (ng)

20.5+ 7.9

25.15+9.7

0.6985

Microalbumin (ug)

18.4+ 7.3

32.9+9.7

0.2474

Hsp90 α (ng)

0.92+ .4

0.9+.3

0.967

VEGF (pg)

2453.0+ 972.5

2900.9+1168

0.7555

proANP (nmol)

0.3+.1

0.5+.1

0.1276

Myoglobin (ng)

15.5+9.8

36.9+4.8

0.0332*

NGAL (ng)

0.08+.1

0.3+.12

0.0984

IL6 (pg)

0.86+.4

3.8+ 8.9

0.1909

IL1 α (pg)

3.8+3.8

1.74+1.07

0.6247

IL1 β (pg)

2.2+1.0

2.5+.5

0.8124

* significant p < .05
values expressed as mean + standard error of the mean (SEM)
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Table 13. Comparison of Assay Results in Female Control and Cocaine Positive Urine

Female
Assay
Control
Total Protein (pg)
Aldosterone (pg)
hsCRP (ng)
Myeloperoxidase (ng)
Microalbumin (ug)
Hsp90 α (ng)
VEGF (pg)
proANP (nmol)
Myoglobin (ng)
NGAL (ng)
IL6 (pg)
IL1 α (pg)
IL1 β (pg)

Cocaine Positive

p

65.9+20.8

47.4+3.2

0.4443

4917.96+1159.9

3463.6+723.2

0.3321

202.3+103.0

47.4+34.3

0.2147

187.1+81.3

52.1+22.1

0.1684

41.2+14.4

40.5+10.2

0.9677

0.3+.2

0.02+.1

0.5478

3286.2+1402.6

1308.4+351.9

0.2366

0.34+.1

0.3+.1

0.9436

26.5+9.1

45.9+9.8

0.1657

12.5+9.8

20.2+12.0

0.6309

7.52+4.4

6.3+4.6

0.8475

56.9+12.5

26.2+12.3

0.0963

6.6+1.4

9.5+3.4

0.461

* significant p < .05
values expressed as mean + standard error of the mean (SEM)
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4.3 Tables
Table 14. Male and Female Control and Cocaine Positive Urine Specimen Comparison

Male

Female

Assay
Control

Cocaine Positive

p

Control

Cocaine Positive

p

Total Protein (pg)
32.2 + 12.1

66.9+22.4

0.2377

65.9+20.8

47.4+3.2

0.4443

1907.7 + 356.7

3331.8+399.8

0.0095*

4917.96+1159.9

3463.6+723.2

0.3321

0.78+ .6

42.1+44.4

0.3668

202.3+103.0

47.4+34.3

0.2147

20.5+ 7.9

25.15+9.7

0.6985

187.1+81.3

52.1+22.1

0.1684

18.4+ 7.3

32.9+9.7

0.2474

41.2+14.4

40.5+10.2

0.9677

0.92+ .4

0.9+.3

0.967

0.3+.2

0.02+.1

0.5478

2453.0+ 972.5

2900.9+1168

0.7555

3286.2+1402.6

1308.4+351.9

0.2366

0.3+.1

0.5+.1

0.1276

0.34+.1

0.3+.1

0.9436

15.5+9.8

36.9+4.8

0.0332*

26.5+9.1

45.9+9.8

0.1657

0.08+.1

0.3+.12

0.0984

12.5+9.8

20.2+12.0

0.6309

0.86+.4

3.8+ 8.9

0.1909

7.52+4.4

6.3+4.6

0.8475

3.8+3.8

1.74+1.07

0.6247

56.9+12.5

26.2+12.3

0.0963

2.2+1.0

2.5+.5

0.8124

6.6+1.4

9.5+3.4

0.461

Aldosterone (pg)

hsCRP (ng)

Myeloperoxidase (ng)

Microalbumin (ug)

Hsp90 α (ng)

VEGF (pg)

proANP (nmol)

Myoglobin (ng)

NGAL (ng)

IL6 (pg)
IL1 α (pg)

IL1 β (pg)

* significant p < .05
values expressed as mean + standard error of the mean (SEM)

101

Table 15. Control and Cocaine Positive Male and Female Urine Specimen Comparison

Control

Cocaine Positive

Assay
Male

Female

p

Male

Female

p

Total Protein (pg)
32.2 + 12.1

65.9+20.8

.2294

66.9+22.4

47.4+3.2

.4612

1907.7 + 356.7

4917.96+1159.9

.0223*

3331.8+399.8

3463.6+723.2

.8600

0.78+ .6

202.3+103.0

.0662

42.1+44.4

47.4+34.3

.9275

20.5+ 7.9

187.1+81.3

.0562

25.15+9.7

52.1+22.1

.2140

18.4+ 7.3

41.2+14.4

.1763

32.9+9.7

40.5+10.2

.5995

0.92+ .4

0.3+.2

.2133

0.9+.3

0.02+.1

.0650

2453.0+ 972.5

3286.2+1402.6

.6205

2900.9+1168

1308.4+351.9

.2535

0.3+.1

0.34+.1

.5482

0.5+.1

0.3+.1

.3612

15.5+9.8

26.5+9.1

.393

36.9+4.8

45.9+9.8

.3586

0.08+.1

12.5+9.8

.2213

0.3+.12

20.2+12.0

.1534

0.86+.4

7.52+4.4

.1532

3.8+ 8.9

6.3+4.6

.6521

3.8+3.8

56.9+12.5

.0007*

1.74+1.07

26.2+12.3

.0907

2.2+1.0

6.6+1.4

.0198*

2.5+.5

9.5+3.4

.0846

Aldosterone (pg)

hsCRP (ng)

Myeloperoxidase (ng)

Microalbumin (ug)

Hsp90 α (ng)

VEGF (pg)

proANP (nmol)

Myoglobin (ng)

NGAL (ng)

IL6 (pg)

IL1 α (pg)

IL1 β (pg)

* significant p < .05
values expressed as mean + standard error of the mean (SEM)

102

Chapter 5.0
Discussion

There are well-documented gender based differences in the etiology and
pathophysiology in many disease states [62, 64, 67, 70, 71, 73-75, 78, 93, 127-142].
Gender differences are well known to exist for many important markers of disease
including triglycerides, enzymes such as AST and SGOT, HDL, uric acid, creatine and
hormones. While blood has remained the medium of clinical preference, toxicological
screens however are frequently done on urine. Unlike serum and plasma, urine typically
lacks interference from clotting and compounds such as proteases [143]. It is well
documented that many proteins are expressed in urine, particularly during certain disease
states; in fact, the human urinary proteome contains more than 1500 proteins [144]. Little
is known about the differences in urinary marker expression between males and females.
Recently, the use of urine as a medium to analyze the expression of many proteins
in the body has become more acceptable [145]. Urinary analysis takes advantage of
protein cell and tissue specificity and their alteration over time in response to different
situations [146]. The proteins and peptides in urine are referred to as the urinary
proteome; variation in the levels of these protein biomarkers has been associated with
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certain pathological states. Markers in the urinary proteome have been validated for
inflammation, oxidative stress, cardiovascular dysfunction and renal disorders [144, 145].
Inflammation is a very common, non-specific form of pathophysiology;
myeloperoxidase, C reactive protein, and IL 6 are markers of acute and systemic
inflammation [147, 148]. MPO is also commonly used as an endpoint of oxidative stress
[149]. IL-1α and IL-1β are immunoregulatory cytokines that favor inflammation;
increased expression is associated with fever, inflammation, tissue destruction, shock and
death. The difference between male and female CRP and MPO were close to statistical
significance in control urine. IL-1α and IL-1β expression is also associated with
autoimmune disorders. It is possible that the gender disparity seen in autoimmune
disorders could reflect a chronic, low-level activation of the immune system that might be
seen in elevated interleukins [150]. In control urine, female IL-1α and IL-1β were higher
than male values by a statistically significant amount. Elevated concentrations of
interleukins upregulate acute phase proteins such as IL 6 and CRP. Albuminuria is
associated with cardiovascular disease, kidney dysfunction and DM [151-153]. Urinary
NGAL expression is linked to nephritis and urinary tract infections [105, 154]. Creatinine
is a general marker of myolysis and kidney disease [155, 156]. Myoglobin is another
marker of myolysis; it was considered the gold standard of cardiac markers prior to the
characterization of troponin. There were no significant gender based results in the
analysis of IL6, microalbumin, NGAL or myoglobin. There was a statistically significant
increase in myoglobin demonstrated in male cocaine positive urine specimens as
compared to male control urine.
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Oxidative stress has been implicated in a variety of inflammatory processes. For
example, increased vascular oxidative stress leads to endothelial dysfunction and
hypertension. VEGF, a marker of angiogenesis, may also be elevated by endothelial
dysfunction [157]. Microalbumin expression is enhanced by many of the same
pathophysiological conditions as VEGF. It is linked to increased cardiovascular and renal
risk factors. Neither microalbumin nor VEGF were statistically significant in any
analysis. Increased oxidative stress is implicated in the activation of the RAS and
subsequent elevations in aldosterone. Aldosterone is a renal hormone in the RAS
secreted in response to hypotension. Aldosterone was higher in female control urine,
when compared to male control urine, by a statistically significant amount. There was
also a statistically significant increase in aldosterone in male cocaine positive urine when
compared to male control urine specimens. Increased cardiac concentrations have been
linked to heart failure. It has been observed that inhibition of the RAS results in a decline
in ROS production [65, 66]. proANP is a hypotensive peptide that counteracts the RAS
by inhibiting the release of hormones such as aldosterone and renin [158]. Increased ANP
levels are detected in adult congestive heart failure, chronic renal failure and in severe
essential hypertension [158, 159]. No statistically significant results were seen in this
study in any analysis of proANP.
While there are noted gender based differences in the etiology of cardiac and
vascular disease, particularly in the area of comorbid conditions, underlying blood
pressure and resultant mortality, the basis of the gender dimorphism is unclear. Clearly
hormones may play an important role as cardiac muscle and vascular tissue are
influenced by hormones such as estrogen and testosterone [1, 9, 10, 12, 59-61]. The
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relationship between inflammatory cytokines and gender has not been clearly elucidated,
although some differences in serum levels of risk markers, including lipids and acute
phase proteins have been noted [6, 27, 29, 30, 80-82]. Studies suggest there may be
gender related differences in the regulation of IL-1 so it is possible that the interleukins
serve different functions depending on gender [160, 161]. Mean concentrations of IL 1α
and IL 1β were significantly higher in the control urine of women than in men.
IL-6 has both pro and anti-inflammatory roles depending on the target cell. It has
been dubbed a „myokine‟, a cytokine produced by muscle and elevated during muscle
contraction and has been found to act synergistically with both IL-1 subunits [162, 163].
Elevations in IL-6 frequently precede increases in CRP [164]. It may be possible that
alterations in urinary IL-6 expression were transitory in our study. This could explain the
failure to detect a significant difference in IL6 between control and metabolite positive
urine specimens.
Women tend to have slightly higher serum CRP than men with the same BMI and
age; however, these differences are not pronounced enough to warrant gender-dependent
reference ranges [135, 165]. The role of gender in predisposition to oxidative stress has
yet to be determined. The clinical and prognostic relevance of these differences requires
further research. CRP is an acute phase inflammatory marker considered to be a reliable
prognostic indicator of atherosclerosis and acute myocardial infarction (AMI) [61, 82,
86]. Urinary levels peak approximately 24 hours following the inflammatory event and
are undetectable within 13 to 16 hours. The differences between male and female CRP
means in control urines in this study were just outside of statistical significance
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(p=0.0662). Cocaine metabolites can remain in the urine for 48 to 72 hours following
acute use, whereas CRP in urine quickly wanes. The results from this study suggest that
CRP levels in urine may not be a reliable prognostic indicator for these
pathophysiological processes at least under the conditions of this study.

As a measure of leukocyte infiltration, the concentration of MPO may increase
significantly in an acute infection such as those of the urinary tract Elevated MPO is
linked to adverse outcomes in acute coronary syndromes and can be used to identify
patients at risk for cardiac events in the absence of cardiac necrosis [54, 87]. Elevated
MPO levels have been shown to independently predict increased risk of major adverse
cardiac events including MI at 30 days and 6 months [166]. The predictive value of this
marker has not been fully characterized; however, it is associated with long term adverse
cardiac events as well. The differences between male and female MPO means in control
urines in this study were just outside of statistical significance (p=0.0562).

Cocaine is well absorbed mucosally and metabolized almost immediately by
serum cholinesterase [56]. The serum half-life of cocaine is less than an hour. The
pharmocodynamics do not change substantially for different routes of entry despite
differences in onset of action, peak absorbance and duration of effect [167]. BE and
EME are the primary metabolites; up to 50% of cocaine is transformed to BE and 30 to
40% is metabolized to EME. Although neither metabolite is pharmacologically active,
both BE and EME been shown to elevate blood pressure [43]. The intense cardiotoxic
interaction between ethanol and cocaine was the primary reason for excluding ethanol
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positive urine specimens from analysis. CE has a significantly longer half life than both
cocaine and BE; inclusion of specimens that could potentially contain CE could affect the
expression of biomarkers such as myoglobin, CRP and MPO.
Cocaine increases intracellular oxygen demand, elevates heart rate and arterial
blood pressure [35, 168]. Cocaine use has been linked to hypertension and tachycardia,
although the effects on heart rate are variable [42, 169]. Increases in myocardial oxygen
demand are associated with the induction of oxidative stress. Cocaine use has been
further shown to enhance endothelial permeability, which may be linked to subclinical
cardiovascular disease, vascular dysfunction, kidney disease, hypertension, nephrotic
syndrome, glomerulonephritis, interstitial nephritis, and rhabdomyolysis [34, 49, 58,
115].
Atherosclerosis, an endothelial cell dysfunction, is characterized by the
development of abnormal vascular responses and the expression of proinflammatory and
prothrombotic factors [50]. MPO is expressed as a result of atherosclerotic lesions such
as those seen in chronic cocaine use. Females had a significantly higher mean
concentration than did males. Estradiol has been suggested as a potential endogenous
substrate for MPO in plasma [88]. As with CRP, the differences between male and
female MPO means in control urines were just outside statistical significance (p=0.0562).

Examination of male and female cocaine positive urine specimens yielded no
statistically significant differences. While the male mean Hsp90α was higher than the
female mean (p=.0650), this result is not statistically significant. It should be noted that
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several markers that exhibited significant differences in control urines were no longer
significant in cocaine positive urine. In cocaine positive urine, the mean male aldosterone
was significantly higher than the male control mean (p=0.0095). The female cocaine
positive aldosterone mean was somewhat lower than the control mean although the
difference was not significant. Mean concentrations of aldosterone were significantly
higher in the control urine of women than in men.
Increased vascular oxidative stress may lead to alterations in endothelial function
and may be related to hypertension [26]. The hypertensive effects of cocaine use are well
established [36, 56]. Cocaine has been shown to activate the renin-angiotensin system
(RAS) which contributes to its cardiotoxicity. ProANP is secreted from cardiac atria in
response to myocyte strain and ischemia; increased levels of proANP have been observed
in heart failure, left ventricular dysfunction, coronary artery disease, and renal failure
[170]. The ANP pathway decreases blood pressure in response to hypertension [171].
Elevated proANP is considered predictive in renal failure, AMI and heart failure [172,
173]. ProANP is cleared from the circulation in 60 to 120 minutes; it seems likely that
there would not be a detectable amount in urine unless the specimen was collected within
8 to 12 hours of the pathological insult. There were no significant differences in any
analysis of proANP.
While it well known that cocaine affects the thermoregulating centers of the
brain, it is unclear if this effect is exerted directly or via endogenous cytokines such as
interleukins. IL-1α and IL-1β, acute phase response cytokines, are endogenous pyrogens
capable of resetting the hypothalamus thermoregulatory center to change body
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temperature [91, 174]. Our results suggest that cocaine may induce hyperexia through
the interleukins. The cellular consequences of heat and ischemic stress are quite similar
[175]. If cocaine exerted a significant thermogenic effect in our study following usage,
IL-1α and IL-1β could be anticipated to be elevated in urine specimens of users.
However, there were no significant differences between the urine of the control group
versus the cocaine positive. Unfortunately, no information was available at the time of
urine collection as to donor body temperature. Clearly, this is an important parameter that
needs to be investigated further in a prospective study.
NGAL exists primarily as a monomer in neutrophils and urine; it also occurs as a
complex with matrix metalloproteinase-9 (MMP-9). NGAL is expressed at a low level in
other tissues including the kidney, prostate and epithelia of the respiratory and alimentary
tracts. It is presently being investigated for validation as a biomarker of urinary tract
infections [176]. NGAL is upregulated in processes that include apoptosis, ischemia,
organogenesis and inflammation.
Increased levels of NGAL from acute renal injury can be detected in both urine
and blood within two hours of the insult [57]. Taken in conjunction with its presence in
urine and association with ischemia, NGAL may be a significant marker of cardiac
dysfunction stemming from cocaine use [177-179]. Most cocaine-induced chest pains do
not progress to AMI. The chest pains due to cocaine are induced by myocardial ischemia
via vasospasm. Given the role of NGAL in oxidative and inflammatory processes, we
were surprised not to see a difference in mean values of NGAL expression. The lack of
statistically significant differences did allow us to tentatively rule out UTIs as the basis
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for higher mean NGAL concentrations seen in female urine specimens. Coupled with the
unlikelihood that the entire female cohort suffered from UTIs, the fact that male
specimens had uniformly lower NGAL concentrations than did the females appears to
suggest gender based expression differences.
Myoglobin lacks cardiospecificity; elevated levels are considered strongly
suggestive of AMI – particularly in the presence of other symptoms. Elevated levels of
myoglobin are also associated with rhabdomyolysis, renal failure and trauma [58].
Myoglobin is released within 2 to 4 hours of significant myocardial and/or skeletal
muscle injury. Levels peak 6 to 12 hours following the pathophysiological event;
returning to prenecrotic levels within 36 hours. An estimated 24% of cocaine users
develop rhabdomyolysis [58]. When male control urine specimens were compared to
cocaine positive specimens, there was a statistically significant difference.
The results of this study suggest there are gender-specific and cocaine-based
differences in oxidative and inflammatory cytokine expression in urine. Males and
females exhibit different morbidity and mortality across a wide range of conditions which
suggests basic pathophysiology may control on the incidence of multiple disease
processes.
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Chapter 6.0
Conclusions

The purpose of this study was to investigate whether or not gender differences
may be present in the expression of a number of urinary proteins which may serve as
markers of inflammation and oxidative stress. It was concluded that the urinary
expression of aldosterone, IL-1α and IL-1β appears to be influenced by gender. Mean
aldosterone (p=0.0223), IL1 α (p=.0007) and IL1 β (p=.0198) concentrations were
significantly higher in female control urine when compared to male control urine. The
results for hsCRP (p=.0662) and MPO (p=.0562) were also higher in female control urine
when compared to male control urine; however, they did not reach statistical significance.
The pathophysiological mechanisms associated with gender based differences in marker
expression will require additional prospective study with expanded demographic
information.
The urinary expression of aldosterone and myoglobin in males is influenced by
the use of cocaine. There were statistically significant increases in myoglobin (p=.0095)
and aldosterone (p=.0332) expression in the cocaine positive urine of males. Oxidative
metabolites of cocaine generate significant ROS; much of the pathophysiological damage
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associated with cocaine use stems from oxidative stress and electron transfer[32].
Cocaine use affects almost every organ system; myocardial infarction, arrhythmias, renal
failure, hypertension, atherosclerosis, and rhabdomyolysis are all in the spectrum of acute
and chronic cocaine toxicity [114, 115].
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